PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8
DICTIONARY FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10735514type1.str





chain nodes :
7 8 9 11 12 14 15
ring nodes :
1 2 3 4 5 6
chain bonds :
1-11 1-12 2-9 3-15 4-8 5-14 6-7
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-11 1-12 2-3 2-9 3-4 4-5 4-8 5-6 6-7
exact bonds :
3-15 5-14

G1:H,Ph,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:CLASS
12:CLASS 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ph,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:28:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3717 TO ITERATE

53.8% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 70684 TO 77996
PROJECTED ANSWERS: 4811 TO 6859

L2 50 SEA SSS SAM L1

=> d l2 scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclopentanecarboxylic acid, 2-(hexahydro-2,4,6-trioxo-5-pyrimidinyl)-, ethyl ester (5CI)
MF C12 H16 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L2 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-, compd. with 1,2-dihydroxy-9,10-anthracenedione and N,N'''-(25,26,27,28-tetrapropoxypentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene-5,17-diyl)bis[N'-[(1R)-1-phenylethyl]-1,3,5-triazine-2,4,6-triamine] (2:1:1) (9CI)
MF C62 H72 N12 O4 . C14 H8 O4 . 2 C8 H12 N2 O3

CM 1



CM 2



CM 3



L2 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H20 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Barbituric acid, 5-(2-butoxyethyl)-5-ethyl- (4CI)
MF C12 H20 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Butanoic acid, 4-[[(hexahydro-2,4,6-trioxo-5-pyrimidinyl)phenylmethylene]amino]- (9CI)
MF C15 H15 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Barbituric acid, 5-{1-[(carboxymethyl)amino]methyl}-5-ethyl-, ethyl ester (5CI)
MF C11 H17 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.88	1.09

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:29:12 ON 09 AUG 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 14:34:33 ON 09 AUG 2006
FILE 'REGISTRY' ENTERED AT 14:34:33 ON 09 AUG 2006

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.88	1.09

=> s l1 sss full
FULL SEARCH INITIATED 14:34:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 73142 TO ITERATE

100.0% PROCESSED 73142 ITERATIONS 5772 ANSWERS
SEARCH TIME: 00.00.03

L3 5772 SEA SSS FUL L1

=> d l3 scan

L3 5772 ANSWERS REGISTRY
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-, compd. with 6,6'-[1,3-phenylenebis(methyleneoxy)]bis[N,N-diethyl-N',N'-bis(phenylmethyl)-1,3,5-triazine-2,4-diamine] (1:1) (9CI)
MF C50 H56 N10 O2 . C8 H12 N2 O3

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 5772 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H13 Cl N8 O8 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 5772 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C8 H12 N2 O3 . C5 H6 N2

CM 1



CM 2



L3 5772 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pseudouric acid, 9-allyl-8-thio- (3CI)
MF C8 H10 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ph,Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       168.26     168.47

FILE 'CAPLUS' ENTERED AT 14:35:59 ON 09 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 9 Aug 2006  VOL 145 ISS 7
FILE LAST UPDATED: 8 Aug 2006  (20060808/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4       36159 L3

=> s l3/thu
         36159 L3
        799431 THU/RL
L5        1917 L3/THU
                (L3 (L) THU/RL)

=> s l5 and ((movement(w)disorder) or tremor or Parkinson's or distonia)
MISMATCHED QUOTE 'PARKINSON'S'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s l5 and ((movement(w)disorder) or tremor or Parkinson? or distonia)
        109555 MOVEMENT
        249797 DISORDER
           578 MOVEMENT(W)DISORDER
          4172 TREMOR
         24241 PARKINSON?
             4 DISTONIA
L6          27 L5 AND ((MOVEMENT(W)DISORDER) OR TREMOR OR PARKINSON? OR DISTONI
               A)

=> s l5 and ((movement(w)disorder) or tremor or Parkinson? or dystonia)
        109555 MOVEMENT
        249797 DISORDER
           578 MOVEMENT(W)DISORDER
          4172 TREMOR
         24241 PARKINSON?
          1466 DYSTONIA
L7          28 L5 AND ((MOVEMENT(W)DISORDER) OR TREMOR OR PARKINSON? OR DYSTONI
               A)
```

```
=> s l7 not py>2002
      4170013 PY>2002
L8           8 L7 NOT PY>2002

=> d l8 1-8 ti

L8   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Effects of striatal injections of GABAA receptor agonists and antagonists
     in a genetic animal model of paroxysmal dystonia

L8   ANSWER 2 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Phenytoin-induced choreoathetosis in patients with severe myoclonic
     epilepsy in infancy

L8   ANSWER 3 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Transdermal therapeutic system for application of active agents directly
     via the carotid artery or via superficial branches of the iliac or
     subclavian arteries

L8   ANSWER 4 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Liver injury due to tetrabamate (Atrium): an analysis of 11 cases

L8   ANSWER 5 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Therapeutic treatment and prevention of infections with a bioactive
     material encapsulated within a biodegradable-biocompatible polymeric
     matrix

L8   ANSWER 6 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Lamotrigine substitution study: evidence for synergism with sodium
     valproate?

L8   ANSWER 7 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Effect of antiepileptic drugs on absence-like seizures in the
     tremor rat

L8   ANSWER 8 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Method and agents for preventing tissue injury from hypoxia


=> d l8 1 3 6 7 8 ti abs bib

L8   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Effects of striatal injections of GABAA receptor agonists and antagonists
     in a genetic animal model of paroxysmal dystonia
AB   The underlying mechanisms of idiopathic dystonias are poorly understood.
     The dystonic phenotype in the dtsz mutant hamster, a model of paroxysmal
     dystonia, has been suggested to be based on a deficit of
     γ-aminobutyric acid (GABA)ergic interneurons and changes of the
     GABAA-benzodiazepine receptor complex in the striatum.  In order to
     confirm and extend previous observations, the effects of compds. which
     bind to different sites of the GABAA receptor on the severity of
     dystonia were determined after striatal microinjections in comparison
     to systemic treatments in dtsz mutants.  The GABAA receptor agonist
     (muscimol) and the benzodiazepine (flurazepam) reduced the severity of
     dystonia after striatal and systemic injections.  The antidystonic
     effects of the barbiturate phenobarbital were less marked both after
     striatal and i.p. administration of drugs.  Intrastriatal injections of
     GABA delayed the onset of dystonic attacks.  Striatal and systemic
     treatments with the GABAA receptor antagonist, bicuculline, and with
     pentylenetetrazole, which reduces GABAergic function, accelerated the
     onset of dystonia at subconvulsant doses.  The benzodiazepine
     receptor antagonists flumazenil aggravated dystonia after
     systemic and intrastriatal injections.  In all, the present data
     substantiate the relevance of striatal GABAergic disinhibition in the
     pathogenesis of paroxysmal dystonia in dtsz mutants.
```

AN 2002:417313 CAPLUS
DN 138:23026
TI Effects of striatal injections of GABAA receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia
AU Hamann, Melanie; Richter, Angelika
CS Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine Hannover, Hannover, 30559, Germany
SO European Journal of Pharmacology (2002), 443(1-3), 59-70
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Transdermal therapeutic system for application of active agents directly via the carotid artery or via superficial branches of the iliac or subclavian arteries
AB The invention relates to the transdermal application of active agents in the region of the carotid artery or the superficial branches of the iliac or subclavian arteries. Narrow and/or ribbon-type transdermal therapeutic systems (TTS), which are applied to the course of the carotid artery and the superficial branches of the iliac or subclavian arteries, are particularly suitable for the application. The aim of this type of application is to ensure that active agents selectively reach the corresponding target tissue or areas to be treated as quickly as possible. The invention also relates to the use of the TTS for medical application in various indications. Thus a plaster was prepared by mixing 50 g Selegiline, 20 g permeation enhancer (Brij) and 200 g 1,2-propanediol; the mixture was dispersed in silicon adhesive 4301 from Dow Corning; the dispersion was used to coat a polyethylene terephthalate foil.
AN 2001:868188 CAPLUS
DN 135:376700
TI Transdermal therapeutic system for application of active agents directly via the carotid artery or via superficial branches of the iliac or subclavian arteries
IN Otto, Karlheinz; Selzer, Torsten; Kiehnle, Axel
PA LTS Lohmann Therapie-Systeme A.-G., Germany
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001089489	A2	20011129	WO 2001-EP5475	20010515
	WO 2001089489	A3	20020502		
	W: JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	DE 10025644	A1	20011206	DE 2000-10025644	20000524
PRAI	DE 2000-10025644	A	20000524		

L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Lamotrigine substitution study: evidence for synergism with sodium valproate?
AB Three hundred and forty-seven patients with epilepsy from 54 European centers who were not fully controlled by sodium valproate (VPA), carbamazepine (CBZ), phenytoin (PHT) or phenobarbital (PB) monotherapy were recruited into a lamotrigine (LTG) substitution study. If ≥50% seizure reduction occurred (responders) upon addition of LTG to the regimen, an attempt was made to withdraw the original antiepileptic drug (AED). If successful, this was followed by a 12-wk period of LTG monotherapy. Overall, 73% of the patients completed the add-on phase (47%

responders), 41% attempted AED withdrawal, and 23% achieved LTG monotherapy. In the 60 patients (17%) completing the trial by remaining on LTG monotherapy, median monthly seizure frequency was reduced from 6 during the basal period to 1.7. Sixteen percent of the patients were withdrawn due to adverse effects, mostly during the add-on phase; dizziness and diplopia occurred most frequently in the CBZ-treated group, nervousness and ataxia in the PHT-treated group, and rash and tremor in the VPA-treated group. Slower LTG dose escalation resulted in fewer withdrawals due to rash in the VPA-treated patients. The responder rate was higher in patients with idiopathic tonic-clonic seizures than in those with partial seizures. Addition of LTG to the VPA regimen (64% responders) produced a better response than adding it to the CBZ (41% responders) or the PHT (38% responders) regimens. This effect was seen with partial as well as tonic-clonic seizures. These data lend credence to the suggestion of therapeutic synergy between LTG and VPA.

AN 1997:295563 CAPLUS
DN 126:324954
TI Lamotrigine substitution study: evidence for synergism with sodium valproate?
AU Brodie, M. J.; Yuen, A. W. C.
CS 105 Study Group, Epilepsy Unit, Univ. Dep. Medicine & Therapeutics, Glasgow, G11 6NT, UK
SO Epilepsy Research (1997), 26(3), 423-432
CODEN: EPIRE8; ISSN: 0920-1211
PB Elsevier
DT Journal
LA English

L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Effect of antiepileptic drugs on absence-like seizures in the tremor rat
AB The effects of conventional antiepileptic drugs (AEDs) on absence-like seizures in homozygous tremor rats (tm/tm) were examined to determine if they corresponded pharmacol. to human absence seizures and absence-like seizures in spontaneously epileptic rats (SER: zi/zi, tm/tm) with both tonic convulsive and absence-like seizures. Cortical and hippocampal EEG activity was recorded with chronically implanted electrodes. The effects of AEDS on seizures of the tremor rat showed profiles similar to those observed in human absence seizures and also in absence-like seizures of SER. The absence-like seizures, associated with paroxysmal bursts of 5-7-Hz spike-wave complexes, were inhibited by trimethadione (200 mg/kg, i.p.), ethosuximide (100 and 200 mg/kg, i.p.), valproate (100 mg/kg, i.p.), and phenobarbital (10 and 20 mg/kg, i.p.). Phenytoin (20 mg/kg, i.p.) was ineffective. These results are consistent with the conclusion that the tremor rat is a useful model for evaluating new AEDS for human absence seizures.
AN 1995:844410 CAPLUS
DN 123:275823
TI Effect of antiepileptic drugs on absence-like seizures in the tremor rat
AU Hanaya, R.; Sasa, M.; Ujihara, H.; Fujita, Y.; Amano, T.; Matsubayashi, H.; Serikawa, T.; Uozumi, T.
CS School Medicine, Hiroshima University, Hiroshima, 734, Japan
SO Epilepsia (1995), 36(9), 938-42
CODEN: EPILAK; ISSN: 0013-9580
PB Lippincott-Raven
DT Journal
LA English

L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method and agents for preventing tissue injury from hypoxia
GI



I

AB Tissue injury, caused by tissue hypoxia and reoxygenation, is prevented by administering a xanthine derivative I [R1 = (ω-1) secondary alc.-substituted C5-12 alkyl enantiomer; R2, R3 = C1-12 alkyl or (di)oxaalkyl] or a (heterocyclylalkyl)amine that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid through inhibition of lysophosphatidic acyltransferase. Diseases that can be treated with these compds. include shock, sequelae of myocardial infarction and stroke, altitude sickness, acidosis, hypoxia-mediated neurodegenerative diseases, and disorders related to transplantation and transplant rejection. Thus, in mice with exptl. hemorrhage, treatment with lisophylline (100 mg/kg i.v. after 1 h, then 100 mg/kg i.p. 8 times at 8-h intervals) largely normalized signs of hemorrhagic shock (neutrophil infiltration, interstitial edema, elevated plasma levels of interferon-γ and tumor necrosis factor α, elevated mRNA levels for interleukins 1β and 6 in pulmonary mononuclear cells, etc.).

AN 1995:767627 CAPLUS

DN 124:21803

TI Method and agents for preventing tissue injury from hypoxia

IN Bursten, Stuart L.; Singer, Jack W.; Rice, Glenn C.

PA CE Therapeutics, Inc., USA

SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9513075	A1	19950518	WO 1994-US12821	19941114
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9510907	A1	19950529	AU 1995-10907	19941114
	EP 728003	A1	19960828	EP 1995-901808	19941114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRAI	US 1993-152117	A	19931112		
	WO 1994-US12821	W	19941114		

OS MARPAT 124:21803

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	42.04	210.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

FILE 'REGISTRY' ENTERED AT 14:39:02 ON 09 AUG 2006

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8
DICTIONARY FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10735514type2.str





chain nodes :
7 8 9 11 12 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
ring nodes :
1 2 3 4 5 6
chain bonds :
1-11 1-12 2-9 3-15 4-8 5-14 6-7 14-17 14-22 14-27 15-16 15-21 15-26
16-19 17-18 18-23 18-28 18-29 19-20 19-24 19-25

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-11 1-12 2-3 2-9 3-4 3-15 4-5 4-8 5-6 5-14 6-7 14-17 14-22
15-16 15-21 16-19 17-18 18-23 19-20
exact bonds :
14-27 15-26 18-28 18-29 19-24 19-25

G1:H,Ph,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:CLASS
12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR



G1 H,Ph,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l9
SAMPLE SEARCH INITIATED 14:39:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6 TO 266
PROJECTED ANSWERS: 1 TO 80

L10 1 SEA SSS SAM L9

=> d l10 scan

L10 1 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-1,3-bis(methoxymethyl)-5-(phenyl-

d5)- (9CI)
MF C16 H15 D5 N2 O5



ALL ANSWERS HAVE BEEN SCANNED

=> s l9 sss full
FULL SEARCH INITIATED 14:39:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 129 TO ITERATE

100.0% PROCESSED 129 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.01

L11 21 SEA SSS FUL L9

=> d l11 scan

L11 21 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1,3-bis(ethoxymethyl)-5,5-diphenyl-
(9CI)
MF C22 H24 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L11 21 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1,3-bis(ethoxymethyl)-5-methyl-5-phenyl-
(9CI)
MF C17 H22 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 21 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-1,3-bis(methoxymethyl)-5-(phenyl-d5)- (9CI)
MF C16 H15 D5 N2 O5



L11 21 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-1,3-bis(methoxymethyl-14C)-5-phenyl- (9CI)
MF C16 H20 N2 O5



L11 21 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-1,3-bis[(phenylmethoxy)methyl]- (9CI)
MF C32 H28 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.38	377.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

FILE 'CAPLUS' ENTERED AT 14:40:26 ON 09 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 Aug 2006 VOL 145 ISS 7
FILE LAST UPDATED: 8 Aug 2006 (20060808/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l11/thu
            47 L11
        799431 THU/RL
L12         13 L11/THU
               (L11 (L) THU/RL)

=> s l12 not py>2002
       4170013 PY>2002
L13           6 L12 NOT PY>2002

=> d l13 1-6 ti

L13  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   QSAR study on a series of anticonvulsant barbiturates
```

L13 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmaceutical dosage forms containing antiepileptic drugs and cellulose derivatives and polyalkylene oxides

L13 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Quantum pharmacologic studies applicable to the design of anticonvulsants: Theoretical conformational analysis and structure-activity studies of barbiturates

L13 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Eterobarb [pharmacology]

L13 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Oxopyrimidine derivatives and pharmaceutical compositions containing them

L13 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Anticonvulsants. 3. Phenobarbital and mephobarbital derivatives

=> d l13 1-6 ti abs bib

L13 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI QSAR study on a series of anticonvulsant barbiturates
AB For a series of anticonvulsant barbiturates, a MTD study and a MLR anal. using electronic and steric descriptors were performed. The substituents at N1 and N3 atoms of the barbiturate ring resulted to be important for anticonvulsant activity. The final model contains five electronic and steric descriptors and gives a correlational coefficient r = 0.883. The model can be used to predict anticonvulsant activity for novel barbiturates.
AN 1999:563771 CAPLUS
DN 132:102398
TI QSAR study on a series of anticonvulsant barbiturates
AU Martin, Oana; Simon, Z.; Nutiu, R.; Bologa, C.; Daba, Mihaela
CS Faculty of Chemistry- Biology-Geography, Department of Chemistry, West University of Timisoara, Timisoara, RO-1900, Rom.
SO Annals of West University of Timisoara, Series of Chemistry (1997), 6(1), 111-118
CODEN: AWTCFO; ISSN: 1224-9513
PB West University of Timisoara, Dep. of Chemistry
DT Journal
LA English
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmaceutical dosage forms containing antiepileptic drugs and cellulose derivatives and polyalkylene oxides
AB A pharmaceutical dosage form is disclosed which comprises an antiepileptic drug, cellulose derivs., and polyalkylene oxides. A sustained-release dosage form containing 276 mg phenytoin (I) is disclosed which released 90% of I in 14.7 h from the slow-release section and 90% of I in 5.7 h from the fast release section.
AN 1996:64951 CAPLUS
DN 124:127131
TI Pharmaceutical dosage forms containing antiepileptic drugs and cellulose derivatives and polyalkylene oxides
IN Jao, Frank; Wong, Patrick S-L.; Cruz, Evangeline; Sy, Eduardo C.; Kuczynski, Anthony L.
PA Alza Corp., USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9529665	A1	19951109	WO 1995-US4634	19950414
	W: AU, CA, FI, JP, KR, MX, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ZA 9503078	A	19960105	ZA 1995-3078	19950413
	CA 2184395	AA	19951109	CA 1995-2184395	19950414
	AU 9522912	A1	19951129	AU 1995-22912	19950414
	AU 693546	B2	19980702		
	EP 758228	A1	19970219	EP 1995-916400	19950414
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09512550	T2	19971216	JP 1995-528265	19950414
	US 5660861	A	19970826	US 1995-440264	19950512
	US 5906832	A	19990525	US 1995-439914	19950512
	US 5876750	A	19990302	US 1997-871075	19970609
	US 5955103	A	19990921	US 1997-871748	19970609
	US 5863558	A	19990126	US 1997-955445	19971021
PRAI	US 1994-234092	A	19940428		
	WO 1995-US4634	W	19950414		
	US 1995-439915	B3	19950512		
	US 1995-440010	B3	19950512		

L13 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Quantum pharmacologic studies applicable to the design of anticonvulsants: Theoretical conformational analysis and structure-activity studies of barbiturates

AB The authors report the first large-scale systematic quant. structure-activity relationship (QSAR) study of barbiturates, correlating mol. structures with anticonvulsant activity. To achieve this QSAR study, the authors devised a four-step strategy. In step 1, an optimal quantum mech. technique for determining the geometry and shape (conformation) of barbiturates was ascertained; this is the AM1 semiempirical MO method. In step 2, the AM1 method was used to optimize the structures and mol. properties of 48 barbiturates with varying anticonvulsant activity. In step 3, discriminant anal. and regression anal. statistical calcns. were used to correlate the mol. properties of the 48 analogs against maximal electroshock (MES) and s.c. metrazol (s.c.Met)-induced seizures. In step 4, the contribution of mol. electrostatic properties to barbiturate anticonvulsant activity was further refined by quantum mech. derived mol. electrostatic potential (MEP) maps. Using this four-step strategy, the authors defined the pharmacophore, the portion of a mol. responsible for bioactivity, for anti-MES and anti-s.c.Met activity. For anti-s.c.Met activity, barbiturate lipophilicity and geometry are important considerations; for anti-MES activity, barbiturate topol. and electronic properties have increased relevance.

AN 1994:548342 CAPLUS

DN 121:148342

TI Quantum pharmacologic studies applicable to the design of anticonvulsants: Theoretical conformational analysis and structure-activity studies of barbiturates

AU Bikker, Jack Andrew; Kubanek, Julia; Weaver, Donald F.

CS Dep. Chem. and Med., Queen's Univ. Kingston, Kingston, ON, K7L 3N6, Can.

SO Epilepsia (1994), 35(2), 411-25
CODEN: EPILAK; ISSN: 0013-9580

DT Journal

LA English

L13 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Eterobarb [pharmacology]

AB A review, with 34 refs., of the pharmacol. of the anticonvulsant eterobarb [27511-99-5].

AN 1987:10 CAPLUS

DN 106:10

TI Eterobarb [pharmacology]

AU Gallagher, B. B.

CS Dep. Neurol., Med. Coll. Georgia, Augusta, GA, 30912, USA

SO Current Problems in Epilepsy (1986), 4(New Anticonvulsant Drugs), 103-15
CODEN: CPEPES; ISSN: 0950-4591
DT Journal; General Review
LA English

L13 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Oxopyrimidine derivatives and pharmaceutical compositions containing them
GI



I

AB Barbiturates I [R, R1 = H, alkyl, alkoxyalkyl; R2, R3 = Ph, alkylphenyl, halophenyl] were prepared Thus I (R = R1 = H, R2 = R3 = Ph) was treated with ClCH2OMe to give 70% I (R = R1 = CH2OMe, R2 = R3 = Ph) which at 500 mg/kg orally in rats gave 100% protection in the maximum electroshock test 23 h after administration. I (R = R1 = H, R2 = R3 = 4-MeC6H4) had tranquilizing activity at 200 mg/kg i.p.
AN 1985:487713 CAPLUS
DN 103:87713
TI Oxopyrimidine derivatives and pharmaceutical compositions containing them
IN Levitt, Barrie; Stolar, Morris
PA Taro Pharmaceutical Industries Ltd., Israel
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 137343	A2	19850417	EP 1984-110959	19840913
	EP 137343	A3	19860611		
	EP 137343	B1	19911204		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	IL 69722	A1	19860930	IL 1983-69722	19830914
	US 4628056	A	19861209	US 1984-647680	19840905
	AU 8432875	A1	19850321	AU 1984-32875	19840910
	AU 571265	B2	19880414		
	DK 8404317	A	19850315	DK 1984-4317	19840911
	DK 167615	B1	19931129		
	JP 60084272	A2	19850513	JP 1984-192413	19840913
	JP 07030044	B4	19950405		
	AT 70056	E	19911215	AT 1984-110959	19840913
	ZA 8407274	A	19860430	ZA 1984-7274	19840914
PRAI	IL 1983-69722	A	19830914		
	EP 1984-110959	A	19840913		

OS MARPAT 103:87713

L13 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Anticonvulsants. 3. Phenobarbital and mephobarbital derivatives
AB Several phenobarbital and mephobarbital derivs. had potent activity against maximum electroshock- and pentylenetetrazole-induced seizures in mice without the marked hypnotic effects of the parent compounds. Among these were 1-morpholinomethyl-5-ethyl-5-phenylbarbituric acid ethanolate (I-EtOH) [42061-65-4], 1-piperidinomethyl-5-ethyl-5-phenylbarbituric acid

ethanolate [42061-66-5], and 1,3-bis(bromomethyl)-5-ethyl-5-phenylbarbituric acid bis(hexamethylenetetramine salt) [42061-67-6]. These compounds may be useful therapeutically against both grand and petit mal seizures. 1-Methyl-3-methoxymethylphenobarbital [42061-68-7] was also highly active against pentylenetetrazole seizures, but less active against electroshock seizures.

AN 1973:511550 CAPLUS
DN 79:111550
TI Anticonvulsants. 3. Phenobarbital and mephobarbital derivatives
AU Vida, Julius A.; Hooker, Mary L.; Reinhard, John F.
CS Kendall Co., Lexington, MA, USA
SO Journal of Medicinal Chemistry (1973), 16(6), 602-5
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.24	401.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.50	-8.25

FILE 'REGISTRY' ENTERED AT 14:41:27 ON 09 AUG 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8
DICTIONARY FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10735514type3.str





chain nodes :
7 8 9 11 12 14 15 16 17 18 19 20 21 22
ring nodes :
1 2 3 4 5 6
chain bonds :
1-11 1-12 2-9 3-14 4-8 5-22 6-7 14-15 14-18 14-21 15-16 16-17 16-19
16-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-11 1-12 2-3 2-9 3-4 3-14 4-5 4-8 5-6 6-7 14-15 14-18 15-16
16-17
exact bonds :
5-22 14-21 16-19 16-20

G1:H,Ph,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:CLASS
12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS

L14 STRUCTURE UPLOADED

=> d l14
L14 HAS NO ANSWERS
L14 STR



G1 H,Ph,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l14
SAMPLE SEARCH INITIATED 14:41:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 33 TO 447
PROJECTED ANSWERS: 3 TO 163

L15 3 SEA SSS SAM L14

=> d l15 scan

L15 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-[(2-hydroxyethoxy)methyl]-5-(phenylthio)- (9CI)
MF C13 H14 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L15 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(methoxymethyl)-5,5-dimethyl- (9CI)
MF C8 H12 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-1-(methoxymethyl)-5-phenyl-
(9CI)
MF C14 H16 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l14 sss full
FULL SEARCH INITIATED 14:42:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 231 TO ITERATE

100.0% PROCESSED 231 ITERATIONS 24 ANSWERS
SEARCH TIME: 00.00.01

L16 24 SEA SSS FUL L14

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	568.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.25

FILE 'CAPLUS' ENTERED AT 14:42:12 ON 09 AUG 2006

FILE COVERS 1907 - 9 Aug 2006 VOL 145 ISS 7
FILE LAST UPDATED: 8 Aug 2006 (20060808/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l16/thu
            42 L16
        799431 THU/RL
L17         16 L16/THU
               (L16 (L) THU/RL)

=> s l17 not py>2002
       4170013 PY>2002
L18           7 L17 NOT PY>2002

=> d l18 1-7 ti

L18  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Modulation of 5-fluorouracil host toxicity by 5-
     (benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase
     inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine

L18  ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   QSAR study on a series of anticonvulsant barbiturates

L18  ANSWER 3 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   5-(m-benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine
     phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of
     uridine, as modulators of plasma uridine concentration: Implications for
     chemotherapy

L18  ANSWER 4 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Methods and compositions for inhibiting uridine secretion

L18  ANSWER 5 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine
     phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid
     acyclonucleoside

L18  ANSWER 6 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Quantum pharmacologic studies applicable to the design of anticonvulsants:
     Theoretical conformational analysis and structure-activity studies of
     barbiturates

L18  ANSWER 7 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Metabolism of dimethoxymethylphenobarbital in mice.  Relation between
     brain phenobarbital levels and anticonvulsant activity


=> d l18 1-7 ti abs bib
```

L18 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine
AB Administration of 200 mg/kg of 5-fluorouracil (FUra) to mice bearing human colon carcinoma DLD-1 xenografts resulted in 100% mortality. Oral administration of 2000 mg/kg of 2',3',5'-tri-O-acetyluridine (TAU), a prodrug of uridine, in combination with 120 mg/kg of 5-(benzyloxybenzyl)barbituric acid acyclonucleoside (BBBA), the most potent known inhibitor of uridine phosphorylase (UrdPase, EC 2.4.2.3), 2 h after the administration of the same dose of FUra completely protected the mice (100% survival) from the toxicity of FUra. This combination also reduced tumor weight by 67% compared with 46% achieved by the maximum tolerated dose (50 mg/kg) of FUra alone. Similarly, administration of BBBA plus TAU 1 h before or 4 h after the administration of FUra reduced the tumor weight by 53 and 37%, resp. However, these schedules were less effective in protecting the host from the toxicity of FUra than when the treatment was carried out at 2 h after FUra administration. TAU alone did not protect from FUra host toxicity. The efficiency of the BBBA plus TAU combination in rescuing from FUra host toxicities is attributed to the exceptional effectiveness of this combination in raising and maintaining higher plasma uridine concns. than those achieved by TAU alone or by equimolar doses of uridine (Ashour et al., Biochem. Pharmacol 51: 1601-1612, 1996). The present results suggest that the BBBA plus TAU combination can provide a better substitute for the massive doses of uridine required to achieve the high levels of uridine necessary to rescue or protect from FUra host toxicities without the toxic side-effects associated with such doses of uridine. The combination of TAU plus BBBA may also allow the escalation of FUra doses for better chemotherapeutic efficacy. Alternatively, the combination may be used as a rescue regimen in the occasional cases where cancer patients receive a lethal overdose of FUra.
AN 2000:400538 CAPLUS
DN 133:144540
TI Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine
AU Ashour, O. M.; Naguib, F. N. M.; Panzica, R. P.; Al Safarjalani, O. N.; el Kouni, M. H.
CS Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA
SO Biochemical Pharmacology (2000), 60(3), 427-431
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science Inc. .
DT Journal
LA English
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI QSAR study on a series of anticonvulsant barbiturates
AB For a series of anticonvulsant barbiturates, a MTD study and a MLR anal. using electronic and steric descriptors were performed. The substituents at N1 and N3 atoms of the barbiturate ring resulted to be important for anticonvulsant activity. The final model contains five electronic and steric descriptors and gives a correlational coefficient r = 0.883. The model can be used to predict anticonvulsant activity for novel barbiturates.
AN 1999:563771 CAPLUS
DN 132:102398
TI QSAR study on a series of anticonvulsant barbiturates
AU Martin, Oana; Simon, Z.; Nutiu, R.; Bologa, C.; Daba, Mihaela
CS Faculty of Chemistry- Biology-Geography, Department of Chemistry, West University of Timisoara, Timisoara, RO-1900, Rom.
SO Annals of West University of Timisoara, Series of Chemistry (1997), 6(1), 111-118

CODEN: AWTCFO; ISSN: 1224-9513
PB West University of Timisoara, Dep. of Chemistry
DT Journal
LA English
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI 5-(m-benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration: Implications for chemotherapy
AB 5-(M-benzyloxybenzyl)barbituric acid acyclonucleoside (BBBA), the most potent inhibitor known of uridine phosphorylase (UrdPase, EC 2.4.2.3), the enzyme responsible for uridine catabolism, and 2',3',5'-tri-O-acetyluridine (TAU), a prodrug of uridine, were used to investigate the possibility of improving the bioavailability of oral uridine in mice. Oral BBBA administered at 30, 60, 120, and 240 mg/kg increased the concentration of plasma uridine (2.6±0.7 μM) by 3.2-, 4.6, 5.4-, and 7.2-fold, resp. After administration of 120 and 240 mg/kg BBBA, plasma uridine concentration remained 3- and 6-fold, resp., higher than the plasma concentration at zero time (C0) for over 8 h. BBBA did not change the concentration of plasma uracil. TAU was far more superior than uridine in improving the bioavailability of plasma uridine. The relative bioavailability of plasma uridine released from oral TAU (53%) was 7-fold higher than that (7.7%) obtained by oral uridine. Oral TAU at 460, 1000, and 2000 mg/kg achieved area under the curve (AUC) values of plasma uridine of 82, 288, and 754 μmol·hr/L, resp. Coadministration of BBBA with uridine or TAU further improved the bioavailability of plasma uridine resulting from the administration of either alone and reduced the Cmax and AUC of plasma uracil. Coadministration of BBBA at 30, 60, and 120 mg/kg improved the relative bioavailability of uridine released from 2000 mg/kg TAU (53%) by 1.7-, 2.7-, and 3.9-fold, resp., while coadministration of the same doses of BBBA with an equimolar dose of uridine (1320 mg/kg) increased the relative bioavailability of oral uridine (7.7%) by 4.1-, 5.3-, and 7.8-fold, resp. Moreover, the AUC and Cmax of plasma uridine after BBBA (120 mg/kg) administration with TAU were 3.5- and 11.5-fold, resp., higher than those obtained from coadministration of BBBA with an equimolar dose of uridine. The exceptional effectiveness of the BBBA plus TAU combination in elevating and sustaining high plasma uridine concentration can be useful in the management of medical disorders that are mediated by administration of uridine as well as to rescue or protect from host-toxicities of various chemotherapeutic pyrimidine analogs.
AN 1996:341245 CAPLUS
DN 125:75377
TI 5-(m-benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration: Implications for chemotherapy
AU Ashour, Osama M.; Naguib, Fardos N. M.; el Kouni, Mahmoud H.
CS Dep. Pharmacol. Toxicol., Univ. Alabama Birmingham, Birmingham, AL, 35294, USA
SO Biochemical Pharmacology (1996), 51(12), 1601-1611
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier
DT Journal
LA English

L18 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and compositions for inhibiting uridine secretion
AB Methods and pharmaceutical compns. effective to increase intracellular and plasma uridine concns. are disclosed. Certain compns., such as dilazep,

and methods of using such compns. have been found to be effective to inhibit uridine secretion in a subject, thus increasing uridine concentration The Cmax and Tmax of uridine after injection of 2 mg/kg dilazep and 83.3mg/kg uridine to monkeys was 305.0 and 0.5 as compared with 175.0 μM and 0.5 h for uridine only.

AN 1995:528652 CAPLUS
DN 122:282253
TI Methods and compositions for inhibiting uridine secretion
IN Sommadossi, Jean-Pierre; El Kouni, Mahmoud H.
PA UAB Research Foundation, USA
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9505180	A1	19950223	WO 1994-US8550	19940727
	W: AU, CA, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5567689	A	19961022	US 1993-106225	19930813
	CA 2167688	AA	19950223	CA 1994-2167688	19940727
	CA 2167688	C	20000725		
	AU 9473750	A1	19950314	AU 1994-73750	19940727
	AU 685150	B2	19980115		
	EP 716603	A1	19960619	EP 1994-922759	19940727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09504268	T2	19970428	JP 1994-506981	19940727
	US 5723449	A	19980303	US 1996-589017	19960119
PRAI	US 1993-106225	A	19930813		
	WO 1994-US8550	W	19940727		

L18 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside
AB 5-(Benzyloxybenzyl)barbituric acid acyclonucleoside (BBBA) was recently synthesized as a potent and specific inhibitor of uridine phosphorylase (EC 2.4.2.3), the enzyme responsible for the catabolism of 5-fluoro-2'-deoxyuridine (FdUrd) in many types of tumors that are deficient or have little thymidine phosphorylase (EC 2.4.2.4) activity. The effect of BBBA on modulating the antitumor efficacy of FdUrd was evaluated in vitro, against the human colon carcinomas DLD-1 and HCT-15 grown in culture, and in vivo, against DLD-1 grown as xenografts in anti-thymocyte serum immunosuppressed mice. The concns. of FdUrd that produced 50% growth inhibition after a 3-h exposure were 88 and 340 nM for HCT-15 and DLD-1, resp. BBBA alone, at all concns. tested, had no significant effect on the growth of DLD-1 and HCT-15 in culture. However, BBBA at 5, 10, 20, and 40 nM potentiated the cytotoxicity of FdUrd (340 nM; 3 h) against DLD-1 in culture by 20, 33, 55, and 63%, resp. Similarly, BBBA at 10 and 20 nM potentiated the cytotoxicity of FdUrd (88 nM; 3 h) against HCT-15 in culture by 37 and 45%, resp. In soft agar, BBBA (19 nM) also enhanced the cytocidal effect of FdUrd (10 and 32 nM) against DLD-1 by 41 and 55%, resp., and against HCT-15 by 6 and 31%, resp. Increasing BBBA dose to 20 nM enhanced further the FdUrd (10 and 32 nM) cytotoxicity against DLD-1 by 76 and 77%, resp., and HCT-15 by 31 and 48%, resp. BBBA also potentiated the chemotherapeutic efficacy of FdUrd in anti-thymocyte serum immunosuppressed mice bearing DLD-1 xenografts with no apparent host toxicity. At a low tumor burden (2.5+106 cells/mouse), 2 days treatment with FdUrd alone (50 mg/kg/day + 2) did not result in significant reduction in tumor volume Coadministration of BBBA at 5 and 10 mg/kg/day + 2 did not potentiate the efficacy of FdUrd over that achieved by FdUrd alone, but it significantly reduced the tumor volume by 27 and 32%, resp., when compared with untreated controls. FdUrd alone at 150 mg/kg/day + 2 reduced the tumor volume by 29%.

This reduction in tumor volume was enhanced 1.8-fold by coadministration of BBBA (10 mg/kg/day + 2). At a higher tumor burden (5+106 cells/mouse) and 4 days treatment, BBBA at 10 and 30 mg/kg/day + 4 reduced further the tumor volume produced by FdUrd alone (200 mg/kg/day + 4) by 1.2- and 1.4-fold, resp. At a higher dose of FdUrd (400 mg/kg/day + 4), the potentiation by BBBA (10 and 30 mg/kg/day + 4) was 1.6- and 3.4-fold, resp. Enzyme studies suggest that the lower sensitivity to FdUrd and the better potentiation of FdUrd cytotoxicity by BBBA in DLD-1 as compared to HCT-15 could be attributed to higher uridine phosphorylase activity in DLD-1. There were no significant differences between DLD-1 and HCT-15 in the activities of other enzymes involved in FdUrd metabolism Enzyme studies also indicated that DLD-1 and HCT-15, in contrast to host tissues, contain no thymidine phosphorylase and have higher kinase activities towards FdUrd. Therefore, the enhancement of FdUrd antitumor efficacy by BBBA appears to be due to the specific inhibition of uridine phosphorylase. Such inhibition would selectively prevent catabolism and deactivation of FdUrd in the tumors but not in the host. The selective inhibition of FdUrd catabolism along with the higher thymidine kinase activities in the tumors would channel the metabolism of FdUrd in the tumors towards anabolism and formation of its active metabolite 5-fluoro-dUMP to produce the selective toxicity of FdUrd. These findings may lead to a more successful use of FdUrd in cancer chemotherapy, especially against tumors that lack thymidine phosphorylase.

AN 1995:405180 CAPLUS
DN 122:230279
TI Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside
AU Ashour, Osama M.; Naguib, Fardos N. M.; Khalifa, Mohamed M. A.; Abdel-Raheem, Mahmoud H.; Panzica, Raymond P.; el Kouni, Mahmoud H.
CS Dep. Pharmacology Toxicol., Univ. Alabama, Birmingham, AL, 35294, USA
SO Cancer Research (1995), 55(5), 1092-8
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English

L18 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Quantum pharmacologic studies applicable to the design of anticonvulsants: Theoretical conformational analysis and structure-activity studies of barbiturates
AB The authors report the first large-scale systematic quant. structure-activity relationship (QSAR) study of barbiturates, correlating mol. structures with anticonvulsant activity. To achieve this QSAR study, the authors devised a four-step strategy. In step 1, an optimal quantum mech. technique for determining the geometry and shape (conformation) of barbiturates was ascertained; this is the AM1 semiempirical MO method. In step 2, the AM1 method was used to optimize the structures and mol. properties of 48 barbiturates with varying anticonvulsant activity. In step 3, discriminant anal. and regression anal. statistical calcns. were used to correlate the mol. properties of the 48 analogs against maximal electroshock (MES) and s.c. metrazol (s.c.Met)-induced seizures. In step 4, the contribution of mol. electrostatic properties to barbiturate anticonvulsant activity was further refined by quantum mech. derived mol. electrostatic potential (MEP) maps. Using this four-step strategy, the authors defined the pharmacophore, the portion of a mol. responsible for bioactivity, for anti-MES and anti-s.c.Met activity. For anti-s.c.Met activity, barbiturate lipophilicity and geometry are important considerations; for anti-MES activity, barbiturate topol. and electronic properties have increased relevance.
AN 1994:548342 CAPLUS
DN 121:148342
TI Quantum pharmacologic studies applicable to the design of anticonvulsants:

Theoretical conformational analysis and structure-activity studies of barbiturates
AU Bikker, Jack Andrew; Kubanek, Julia; Weaver, Donald F.
CS Dep. Chem. and Med., Queen's Univ. Kingston, Kingston, ON, K7L 3N6, Can.
SO Epilepsia (1994), 35(2), 411-25
CODEN: EPILAK; ISSN: 0013-9580
DT Journal
LA English

L18 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Metabolism of dimethoxymethylphenobarbital in mice. Relation between brain phenobarbital levels and anticonvulsant activity
AB The anticonvulsant activity of 1,3-bis(dimethoxymethyl)phenobarbital (I) [42013-64-9] in mice was the result of its metabolism to phenobarbital [50-06-6]. The brain level of phenobarbital 3 hrs after oral administration of the ED50 of I (42 mg/kg) was 24.6 μg/g. An equivalent dose of Na phenobarbital [57-30-7] (31 mg/kg) produced a brain phenobarbital level of 25.4 μg/g. Blood and whole-body phenobarbital levels paralleled those in the brain after both I and Na phenobarbital administration. A I metabolite, N-methoxymethylphenobarbital [42013-65-0], was found in the brain after I administration and also had anticonvulsant activity.
AN 1973:542746 CAPLUS
DN 79:142746
TI Metabolism of dimethoxymethylphenobarbital in mice. Relation between brain phenobarbital levels and anticonvulsant activity
AU Rapport, Richard L., II; Kupferberg, Harvey J.
CS Natl. Inst. Neurol. Dis. Stroke, Natl. Inst. Health, Bethesda, MD, USA
SO Journal of Medicinal Chemistry (1973), 16(6), 599-602
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English

=> d hisd
'HISD' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

```
OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):dis
'DIS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
```

```
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):ti

L18  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Modulation of 5-fluorouracil host toxicity by 5-
     (benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase
     inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine


=> d his

     (FILE 'HOME' ENTERED AT 14:27:48 ON 09 AUG 2006)

     FILE 'REGISTRY' ENTERED AT 14:28:00 ON 09 AUG 2006
L1             STRUCTURE UPLOADED
L2              50 S L1
L3            5772 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:35:59 ON 09 AUG 2006
L4           36159 S L3
L5            1917 S L3/THU
L6              27 S L5 AND ((MOVEMENT(W)DISORDER) OR TREMOR OR PARKINSON? OR DIST
L7              28 S L5 AND ((MOVEMENT(W)DISORDER) OR TREMOR OR PARKINSON? OR DYST
L8               8 S L7 NOT PY>2002

     FILE 'REGISTRY' ENTERED AT 14:39:02 ON 09 AUG 2006
L9             STRUCTURE UPLOADED
L10             1 S L9
L11            21 S L9 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:40:26 ON 09 AUG 2006
L12             13 S L11/THU
L13              6 S L12 NOT PY>2002

     FILE 'REGISTRY' ENTERED AT 14:41:27 ON 09 AUG 2006
L14            STRUCTURE UPLOADED
```

```
L15             3 S L14
L16            24 S L14 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:42:12 ON 09 AUG 2006
L17            16 S L16/THU
L18             7 S L17 NOT PY>2002

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      27.10     595.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.25     -13.50

STN INTERNATIONAL LOGOFF AT 14:43:46 ON 09 AUG 2006
```

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8
DICTIONARY FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10735514diphenyl.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:29:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11 TO 389
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 09:29:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 137 TO ITERATE

100.0% PROCESSED 137 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.01

L3 15 SEA SSS FUL L1

=> d l3 scan

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl- (9CI)
MF C16 H12 N2 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-, monolithium salt (9CI)
MF C16 H12 N2 O3 . Li



● Li

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-, lithium salt (9CI)
MF C16 H12 N2 O3 . x Li



●x Li

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-, sodium salt (9CI)
MF C16 H12 N2 O3 . x Na



●x Na

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Program Files\Stnexp\Queries\10735514diphenyl2.str

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 09:30:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED         1 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            1 TO        80
PROJECTED ANSWERS:               0 TO         0

L5             0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 09:30:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       12 TO ITERATE

100.0% PROCESSED        12 ITERATIONS                                  4 ANSWERS
SEARCH TIME: 00.00.01

L6             4 SEA SSS FUL L4

=> d l6 scan

L6   4 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
IN   2,4,6(1H,3H,5H)-Pyrimidinetrione, 1,3-bis(butoxymethyl)-5,5-diphenyl-
     (9CI)
MF   C26 H32 N2 O5
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L6 4 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1,3-bis(ethoxymethyl)-5,5-diphenyl-(9CI)
MF C22 H24 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 4 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1,3-bis(methoxymethyl)-5,5-diphenyl-(9CI)
MF C20 H20 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 4 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diphenyl-1,3-bis[(phenylmethoxy)methyl]- (9CI)
MF C32 H28 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> sel l3
E1 THROUGH E20 ASSIGNED

=> sel l6
E21 THROUGH E24 ASSIGNED

=> index bioscience patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	340.59	340.80

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 09:30:58 ON 10 AUG 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s E1-E20
```
          1   FILE ADISCTI
          1   FILE ANABSTR
         10   FILE BIOSIS
  10 FILES SEARCHED...
  14 FILES SEARCHED...
         48   FILE CAPLUS
          1   FILE CIN
          1   FILE CONFSCI
          6   FILE DDFU
  22 FILES SEARCHED...
          1   FILE DRUGMONOG2
          6   FILE DRUGU
          6   FILE EMBASE
          2   FILE ESBIOBASE
  30 FILES SEARCHED...
         13   FILE IFIPAT
          1   FILE IMSPRODUCT
  42 FILES SEARCHED...
          6   FILE MEDLINE
          1   FILE PASCAL
  48 FILES SEARCHED...
          5   FILE SCISEARCH
         15   FILE TOXCENTER
```

```
        14   FILE USPATFULL
  61 FILES SEARCHED...
         4   FILE USPAT2
         4   FILE WPIDS
  66 FILES SEARCHED...
         4   FILE WPINDEX
  68 FILES SEARCHED...
         2   FILE CAOLD
         5   FILE CASREACT
         5   FILE EPFULL
  73 FILES SEARCHED...
  77 FILES SEARCHED...
         7   FILE INPADOC
  84 FILES SEARCHED...
  85 FILES SEARCHED...
        10   FILE PCTFULL
  87 FILES SEARCHED...

  26 FILES HAVE ONE OR MORE ANSWERS,   92 FILES SEARCHED IN STNINDEX

L7   QUE ("BARBITURIC ACID, 5,5-BIS(4,3-CRESYL)-"/BI OR EPIAL/BI OR "NSC 80540"
         /BI OR 155653-19-3/BI OR 21914-07-8/BI OR 246516-40-5/BI OR 305367-91-
         3/BI OR "5,5-DIPHENYLBARBITURIC ACID COMPD. WITH 9-ETHYLADENINE (1:1)"
         /BI OR "5,5-DIPHENYLBARBITURIC ACID"/BI OR 64038-07-9/BI OR 8074-43-9/
         BI OR 861302-61-6/BI OR 875752-96-8/BI OR 875752-97-9/BI OR 875752-98-
         0/BI OR 888711-26-0/BI OR 888711-28-2/BI OR 92978-04-6/BI OR 92978-05-
         7/BI OR 97846-23-6/BI)

=> file biosis embase medline scisearch uspatfull pctfull caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 7.93     348.73

FILE 'BIOSIS' ENTERED AT 09:38:49 ON 10 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 09:38:49 ON 10 AUG 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 09:38:49 ON 10 AUG 2006

FILE 'SCISEARCH' ENTERED AT 09:38:49 ON 10 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 09:38:49 ON 10 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 09:38:49 ON 10 AUG 2006
COPYRIGHT (C) 2006 Univentio

FILE 'CAPLUS' ENTERED AT 09:38:49 ON 10 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s E1-E20
   6 FILES SEARCHED...
L8          99 ("BARBITURIC ACID, 5,5-BIS(4,3-CRESYL)-"/BI OR EPIAL/BI OR "NSC
               80540"/BI OR 155653-19-3/BI OR 21914-07-8/BI OR 246516-40-5/BI
              OR 305367-91-3/BI OR "5,5-DIPHENYLBARBITURIC ACID COMPD. WITH
              9-ETHYLADENINE (1:1)"/BI OR "5,5-DIPHENYLBARBITURIC ACID"/BI OR
              64038-07-9/BI OR 8074-43-9/BI OR 861302-61-6/BI OR 875752-96-8/BI
               OR 875752-97-9/BI OR 875752-98-0/BI OR 888711-26-0/BI OR 888711-
              28-2/BI OR 92978-04-6/BI OR 92978-05-7/BI OR 97846-23-6/BI)
```

```
=> dup rem l8
PROCESSING COMPLETED FOR L8
L9            76 DUP REM L8 (23 DUPLICATES REMOVED)

=> s l9 and (parkinson? or (movement(w)disorder) or tremor or dystonia)
L10           5 L9 AND (PARKINSON? OR (MOVEMENT(W) DISORDER) OR TREMOR OR DYSTO
                NIA)

=> d l10 1-5 ti

L10  ANSWER 1 OF 5  USPATFULL on STN
TI     Composition and method for improved bioavailability and enhanced brain
       delivery of 5,5-diphenyl barbituric acid

L10  ANSWER 2 OF 5  USPATFULL on STN
TI     Method of treating movement disorders using barbituric acid derivatives

L10     ANSWER 3 OF 5      PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN
       DELIVERY OF 5,5-DIPHENYL BARBITURIC ACID
TIFR   COMPOSITION ET PROCEDE PERMETTANT UNE MEILLEURE BIODISPONIBILITE ET
       ADMINISTRATION RENFORCEE D'ACIDE 5,5 DIPHENYL-BARBITURIQUE AU CERVEAU

L10     ANSWER 4 OF 5      PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   METHOD OF TREATING MOVEMENT DISORDERS USING BARBITURIC ACID DERIVATIVES
TIFR   METHODE DE TRAITEMENT DE TROUBLES MOTEURS A L'AIDE DE DERIVES DE L'ACIDE
       BARBITURIQUE

L10  ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Composition and method for enhanced delivery of 5,5-diphenyl barbituric
     acid


=> d l10 1-5 ti abs bib

L10  ANSWER 1 OF 5  USPATFULL on STN
TI     Composition and method for improved bioavailability and enhanced brain
       delivery of 5,5-diphenyl barbituric acid
AB     The present invention relates to a composition and a method of
       delivering a barbituric acid derivative to the central nervous system of
       a mammal in need of treatment for neurological conditions. In
       particular, the present invention relates to a method of administering
       an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to
       enhance the bioavailability of 5,5-diphenyl barbituric acid and brain
       delivery of same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2006:144689  USPATFULL
TI     Composition and method for improved bioavailability and enhanced brain
       delivery of 5,5-diphenyl barbituric acid
IN     Gutman, Daniella, Rishon Lezion, ISRAEL
       Moros, Daniel, Larchmont, NY, UNITED STATES
       Yacobi, Avraham, Englewood, NJ, UNITED STATES
       Rutman, Howard, New York, NY, UNITED STATES
PI     US 2006122208      A1   20060608
AI     US 2005-201024     A1   20050810 (11)
RLI    Continuation-in-part of Ser. No. US 2003-735514, filed on 11 Dec 2003,
       PENDING Continuation-in-part of Ser. No. US 2003-354146, filed on 30 Jan
       2003, GRANTED, Pat. No. US 6939873 Continuation-in-part of Ser. No. US
       2004-865428, filed on 10 Jun 2004, PENDING Continuation of Ser. No. US
       2003-333957, filed on 27 Jan 2003, GRANTED, Pat. No. US 6756379 A 371 of
       International Ser. No. WO 2001-US23420, filed on 26 Jul 2001
PRAI   US 2004-600327P     20040810 (60)
```

US 2002-432470P 20021211 (60)
US 2002-352273P 20020130 (60)
US 2000-221672P 20000726 (60)
DT Utility
FS APPLICATION
LREP TARO PHARMACEUTICALS U.S.A., INC., 3 SKYLINE DRIVE, HAWTHORNE, NY, 10532, US
CLMN Number of Claims: 69
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 1735
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 5 USPATFULL on STN
TI Method of treating movement disorders using barbituric acid derivatives
AB A method of treating movement disorders comprises administering to a human or animal subject in need of treatment a therapeutically effective amount of at least one compound according to the following formula: ##STR1##

wherein R.sub.3 and R.sub.4 are each independently selected from the group consisting of lower alkyl, phenyl and lower alkyl substituted phenyl, and R.sub.1 and R.sub.2 are each independently either a hydrogen atom or a radical of the formula ##STR2##

wherein R.sub.5 and R.sub.6 are each independently selected from the group consisting of H, lower alkyl, phenyl and lower alkyl substituted phenyl, its pharmaceutically acceptable salts, prodrugs, and metabolites thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:240305 USPATFULL
TI Method of treating movement disorders using barbituric acid derivatives
IN Moros, Daniel A., Larchmont, NY, UNITED STATES
PA TARO PHARMACEUTICALS IRELAND LIMITED (U.S. corporation)
PI US 2004186120 A1 20040923
AI US 2003-735514 A1 20031211 (10)
PRAI US 2002-432470P 20021211 (60)
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1358
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5,5-DIPHENYL BARBITURIC ACID
TIFR COMPOSITION ET PROCEDE PERMETTANT UNE MEILLEURE BIODISPONIBILITE ET ADMINISTRATION RENFORCEE D'ACIDE 5,5 DIPHENYL-BARBITURIQUE AU CERVEAU
ABEN The present invention relates to a composition and method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.
ABFR L'invention concerne une composition et un procede permettant d'administrer un derive d'acide barbiturique au systeme nerveux central d'un mammifere necessitant un traitement d'etats neurologiques. Plus precisement, l'invention concerne un procede permettant d'administrer par voie orale une forme posologique d'un sel de sodium d'acide

5,5-diphenyl-barbiturique afin de renforcer la biodisponibilite de l'acide 5,5-diphenyl-barbiturique ainsi que son administration au cerveau.

AN 2006026095 PCTFULL ED 20060403 EW 200610

TIEN COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5,5-DIPHENYL BARBITURIC ACID

TIFR COMPOSITION ET PROCEDE PERMETTANT UNE MEILLEURE BIODISPONIBILITE ET ADMINISTRATION RENFORCEE D'ACIDE 5,5 DIPHENYL-BARBITURIQUE AU CERVEAU

IN GUTMAN, Daniella, 12 Hirschfield Street, 75421 Rishon Lezion, IL;
RUTMAN, Howard, 401 East 80th Street, New York, NY 10021, US;
MOROS, Daniel, 19 Maple Avenue, Larchmong, NY 10538, US;
LEVITT, Barrie, 16 Stonewall Lane, Mamaroneck, NY 10543, US;
YACOBI, Avraham, 13 Oak Trail Road, Englewood, NJ 07631, US

PA TARO PHARMACEUTICAL INDUSTRIES LTD., 14 Hakitor Street, 26110 Haifa Bay, IL;
GUTMAN, Daniella, 12 Hirschfield Street, 75421 Rishon Lezion, IL;
RUTMAN, Howard, 401 East 80th Street, New York, NY 10021, US;
MOROS, Daniel, 19 Maple Avenue, Larchmong, NY 10538, US;
LEVITT, Barrie, 16 Stonewall Lane, Mamaroneck, NY 10543, US;
YACOBI, Avraham, 13 Oak Trail Road, Englewood, NJ 07631, US

AG LO, Siu, K., Taro Pharmaceuticals U.S.A., Inc., 3 Skyline Drive, Hawthorne, NY 10532; 10532, US

LAF English

LA English

DT Patent

PI WO 2006026095 A2 20060309

DS W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2005-US28380 A 20050810

PRAI US 2004-60600327 20040810

L10 ANSWER 4 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN METHOD OF TREATING MOVEMENT DISORDERS USING BARBITURIC ACID DERIVATIVES

TIFR METHODE DE TRAITEMENT DE TROUBLES MOTEURS A L'AIDE DE DERIVES DE L'ACIDE BARBITURIQUE

ABEN A method of treating movement disorders comprises administering to a human or animal subject in need of treatment a therapeutically effective amount of at least one compound according to the following formula: wherein R<sb>3</sb> and R<sb>4</sb>are each independently selected from the group consisting of lower alkyl, phenyl and lower alkyl substituted phenyl, and R<sb>1</sb> and R<sb>2</sb> are each independently either a hydrogen atom or a radical of the formula wherein R<sb>5</sb>and R<sb>6</sb> are each independently selected from the group consisting of H, lower alkyl, phenyl and lower alkyl substituted phenyl, its pharmaceutically acceptable salts, prodrugs, and metabolites thereof.

ABFR L'invention concerne une methode de traitement de troubles moteurs consistant a administrer a un humain ou a un animal necessitant un tel traitement une dose therapeutique d'au moins un compose represente par la formule generale (I) dans laquelle R<sb>3</sb> et

R<sb>4</sb>designent chacun independamment un element selectionne dans le groupe comprenant un alkyle inferieur, un phenyle et un phenyle substitue par un alkyle inferieure, et R<sb>1</sb> et R<sb>2</sb>designent chacun independamment soit un atome d'hydrogene, soit un radical represente par la formule generale (II) dans laquelle R<sb>5</sb> et R<sb>6</sb> designent chacun independamment un element selectionne dans le groupe comprenant un atome d'hydrogene, un alkyle inferieur, un phenyle et un phenyle substitue par un alkyle inferieur. L'invention concerne egalement des sels de qualite pharmaceutique, des promedicaments et des metabolites de ce compose.

AN 2004052350 PCTFULL ED 20040630 EW 200426
TIEN METHOD OF TREATING MOVEMENT DISORDERS USING BARBITURIC ACID DERIVATIVES
TIFR METHODE DE TRAITEMENT DE TROUBLES MOTEURS A L'AIDE DE DERIVES DE L'ACIDE BARBITURIQUE
IN MOROS, Daniel Aaron, 50 Iselin Terrace, Larchmont, NY 10538, US [US, US]
PA TARO PHARMACEUTICALS IRELAND LIMITED, 25-28 North Wall Quay, Dublin 1, IE [IE, IE], for all designates States except US; MOROS, Daniel Aaron, 50 Iselin Terrace, Larchmont, NY 10538, US [US, US], for US only
AG GOGORIS, Adda, C., Darby & Darby P.C., P,O. Box 5257, New York, NY 10150-5257, US
LAF English
LA English
DT Patent
PI WO 2004052350 A2 20040624
DS W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2003-US39530 A 20031211
PRAI US 2002-60/432,470 20021211

L10 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
AB The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurol. conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-di-Ph barbituric acid (I) to enhance the bioavailability of 5,5-di-Ph barbituric acid and brain delivery of same. I was prepared by the reaction of 5,5-di-Ph barbituric acid with sodium hydroxide. Oral administration of 75 mg/kg I increased the bioavailability of 75 mg/kg 5,5-di-Ph barbituric acid in dogs.
AN 2006:142534 CAPLUS
DN 144:219186
TI Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
IN Levitt, Barrie; Moros, Daniel; Yacobi, Avraham; Gutman, Daniella
PA Taro Pharmaceuticals North America, Inc., Cayman I.
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 5
PATENT NO. KIND DATE APPLICATION NO. DATE

```
     --------------      ----   --------    --------------------   --------
PI   EP 1625848           A1    20060215    EP 2005-290804          20050412
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
            BA, HR, IS, YU
     WO 2006026095        A2    20060309    WO 2005-US28380         20050810
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
            NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
            SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
            ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
PRAI US 2004-600327P      P     20040810
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s l9 not py>2002
L11          55 L9 NOT PY>2002

=> index bioscience patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     109.51     458.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.75      -0.75

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 09:42:04 ON 10 AUG 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s E21-E24
            8   FILE CAPLUS
  36 FILES SEARCHED...
            1   FILE IFIPAT
            1   FILE TOXCENTER
            3   FILE CASREACT
  70 FILES SEARCHED...
  87 FILES SEARCHED...

   4 FILES HAVE ONE OR MORE ANSWERS,    92 FILES SEARCHED IN STNINDEX

L12  QUE (64915-85-1/BI OR 64915-86-2/BI OR 873108-43-1/BI OR 97846-21-4/BI)

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.22     459.46
```

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -0.75

FILE 'CAPLUS' ENTERED AT 09:43:30 ON 10 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 10 Aug 2006  VOL 145 ISS 7
FILE LAST UPDATED: 9 Aug 2006  (20060809/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s E21-E24
             1 64915-85-1/BI
             1 64915-86-2/BI
             1 873108-43-1/BI
             7 97846-21-4/BI
L13          8 (64915-85-1/BI OR 64915-86-2/BI OR 873108-43-1/BI OR 97846-21-4/
               BI)

=> s l13 and (parkinson? or (movement(w)disorder) or tremor or dystonia)
         24249 PARKINSON?
        109589 MOVEMENT
        249823 DISORDER
           578 MOVEMENT(W)DISORDER
          4173 TREMOR
          1466 DYSTONIA
L14          1 L13 AND (PARKINSON? OR (MOVEMENT(W)DISORDER) OR TREMOR OR DYSTON
               IA)

=> d l14

L14  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:513524  CAPLUS
DN   141:47363
TI   Method of treating movement disorders using barbituric acid derivatives
IN   Moros, Daniel Aaron
PA   Taro Pharmaceuticals Ireland Limited, Ire.
SO   PCT Int. Appl., 48 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 5
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   WO 2004052350        A2    20040624    WO 2003-US39530         20031211
     WO 2004052350        A3    20040923
```

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
            NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
            TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
            ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
            TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2505335          AA    20040624    CA 2003-2505335        20031211
    AU 2003302897       A1    20040630    AU 2003-302897         20031211
    EP 1569627          A2    20050907    EP 2003-812970         20031211
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    BR 2003017289       A     20051108    BR 2003-17289          20031211
    CN 1717235          A     20060104    CN 2003-80104405       20031211
    JP 2006510659       T2    20060330    JP 2004-558727         20031211
PRAI US 2002-432470P    P     20021211
    WO 2003-US39530     W     20031211
OS  MARPAT 141:47363


=> d l13 1-8 ti

L13  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Process for N-alkoxyalkylation of ureides with alkoxyalkyl sulfonates with
     amine or hydride bases

L13  ANSWER 2 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Catalytic dealkylation process for preparing 1-methoxymethyl-5,5-
     diphenylbarbituric acid from 1,3-bis(methoxymethyl)-5,5-diphenylbarbituric
     acid using a Lewis acid

L13  ANSWER 3 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Method of treating movement disorders using barbituric acid derivatives

L13  ANSWER 4 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Non-sedating barbiturate compounds as neuroprotective agents

L13  ANSWER 5 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   N-alkoxyalkylation of ureides.

L13  ANSWER 6 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Method for the determination of 5,5-diphenylbarbituric acid and its
     separation from 1,3-dimethoxymethyl-5,5-diphenylbarbituric acid in plasma
     by high-performance liquid chromatography

L13  ANSWER 7 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Oxopyrimidine derivatives and pharmaceutical compositions containing them

L13  ANSWER 8 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Barbituric acid derivatives used as anticonvulsant agents


=> d l13 8 ti abs bib

L13  ANSWER 8 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Barbituric acid derivatives used as anticonvulsant agents
GI
```



I

AB The title compds. I (R = Et, allyl, R1 = Ph, MeCHEt, R2 = Me, PhCH2, Bu, Et, dodecyl) were prepared by treatment of the corresponding Na salt of barbituric acid with ClCH2OR2. ED50 for mice tested against Metrazole were 7 mg/kg for I (R = R1 = Et, R2 = Me) to 200 mg/kg for I (R = R1 = Et, R2 = C12H25).

AN 1978:6934 CAPLUS

DN 88:6934

TI Barbituric acid derivatives used as anticonvulsant agents

IN Samour, Carlos M.; Vida, Julius A.

PA Bristol-Myers Co., USA

SO U.S., 5 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4046894	A	19770906	US 1971-125813	19710318
	US 4249005	A	19810203	US 1969-888943	19691229
	US 3923995	A	19751202	US 1974-472983	19740524
	US 4339454	A	19820713	US 1978-930778	19780803
PRAI	US 1968-749972	A2	19680805		
	US 1969-888943	A3	19691229		
	US 1971-125813	A3	19710318		
	US 1977-798532	A3	19770519		

=> d his

(FILE 'HOME' ENTERED AT 09:28:43 ON 10 AUG 2006)

FILE 'REGISTRY' ENTERED AT 09:28:57 ON 10 AUG 2006

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 15 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 0 S L4
L6 4 S L4 SSS FULL
SEL L3
SEL L6

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 09:30:58 ON 10 AUG 2006

SEA E1-E20

1	FILE ADISCTI
1	FILE ANABSTR
10	FILE BIOSIS
48	FILE CAPLUS
1	FILE CIN
1	FILE CONFSCI
6	FILE DDFU

```
                1   FILE DRUGMONOG2
                6   FILE DRUGU
                6   FILE EMBASE
                2   FILE ESBIOBASE
               13   FILE IFIPAT
                1   FILE IMSPRODUCT
                6   FILE MEDLINE
                1   FILE PASCAL
                5   FILE SCISEARCH
               15   FILE TOXCENTER
               14   FILE USPATFULL
                4   FILE USPAT2
                4   FILE WPIDS
                4   FILE WPINDEX
                2   FILE CAOLD
                5   FILE CASREACT
                5   FILE EPFULL
                7   FILE INPADOC
               10   FILE PCTFULL
L7              QUE ("BARBITURIC ACID, 5,5-BIS(4,3-CRESYL)-"/BI OR EPIAL/BI OR
                ---------

     FILE 'BIOSIS, EMBASE, MEDLINE, SCISEARCH, USPATFULL, PCTFULL, CAPLUS'
     ENTERED AT 09:38:49 ON 10 AUG 2006
L8             99 S E1-E20
L9             76 DUP REM L8 (23 DUPLICATES REMOVED)
L10             5 S L9 AND (PARKINSON? OR (MOVEMENT(W)DISORDER) OR TREMOR OR DYS
L11            55 S L9 NOT PY>2002

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 09:42:04 ON 10 AUG 2006
                SEA E21-E24
                ---------
                8   FILE CAPLUS
                1   FILE IFIPAT
                1   FILE TOXCENTER
                3   FILE CASREACT
L12             QUE (64915-85-1/BI OR 64915-86-2/BI OR 873108-43-1/BI OR 97846-
                ---------

     FILE 'CAPLUS' ENTERED AT 09:43:30 ON 10 AUG 2006
L13             8 S E21-E24
L14             1 S L13 AND (PARKINSON? OR (MOVEMENT(W)DISORDER) OR TREMOR OR DYS
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 AUG 2006 HIGHEST RN 900096-56-2
DICTIONARY FILE UPDATES: 9 AUG 2006 HIGHEST RN 900096-56-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s phenobarbital/cn
L1 1 PHENOBARBITAL/CN

=> sel l1
E1 THROUGH E59 ASSIGNED

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 50-06-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Barbituric acid, 5-ethyl-5-phenyl- (8CI)
OTHER NAMES:
CN 5-Ethyl-5-phenylbarbituric acid
CN 5-Phenyl-5-ethylbarbituric acid
CN Adonal
CN Agrypnal
CN Amylofene
CN Barbenyl
CN Barbiphenyl
CN Barbipil
CN Barbita
CN Barbivis
CN Blu-phen
CN Cratecil
CN Dormiral
CN Doscalun
CN Duneryl
CN Eskabarb
CN Etilfen
CN Euneryl
CN Fenemal
CN Fenemal recip
CN Gardenal
CN Gardepanyl
CN Hysteps
CN Lepinal
CN Lepinaletten
CN Liquital
CN Lixophen

CN Lubergal
CN Luminal
CN Neurobarb
CN Noptil
CN NSC 128143
CN NSC 9848
CN Nunol
CN Phenaemal
CN Phenemal
CN Phenobar
CN Phenobarbital
CN Phenobarbitone
CN Phenobarbituric acid
CN Phenoluric
CN Phenonyl
CN Phenylethylbarbituric acid
CN Phenylethylmalonylurea
CN Phenyral
CN Phob
CN Sedonal
CN Sedophen
CN Sevenal
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS 3D CONCORD
DR 11097-06-6, 46755-67-3
MF C12 H12 N2 O3
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15242 REFERENCES IN FILE CA (1907 TO DATE)
103 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
15257 REFERENCES IN FILE CAPLUS (1907 TO DATE)
95 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> index bioscience patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.43	7.64

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,

```
      AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
      CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
      DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:44:01 ON 10 AUG 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (E1-E59) and Parkinson?
         11   FILE ADISCTI
          5   FILE ADISINSIGHT
         10   FILE ADISNEWS
         31   FILE BIOSIS
          3   FILE BIOTECHABS
          3   FILE BIOTECHDS
  12 FILES SEARCHED...
          6   FILE BIOTECHNO
         48   FILE CAPLUS
         55   FILE DDFB
         46   FILE DDFU
  22 FILES SEARCHED...
          4   FILE DGENE
         55   FILE DRUGB
         78   FILE DRUGU
        177   FILE EMBASE
          6   FILE ESBIOBASE
  30 FILES SEARCHED...
         33   FILE IFIPAT
          3   FILE IMSRESEARCH
          1   FILE JICST-EPLUS
          4   FILE LIFESCI
  43 FILES SEARCHED...
         32   FILE MEDLINE
          6   FILE PASCAL
  48 FILES SEARCHED...
          2   FILE PHIN
          8   FILE PROMT
         27   FILE SCISEARCH
         37   FILE TOXCENTER
       2116   FILE USPATFULL
        266   FILE USPAT2
  62 FILES SEARCHED...
         56   FILE WPIDS
  66 FILES SEARCHED...
         56   FILE WPINDEX
  68 FILES SEARCHED...
        207   FILE EPFULL
         15   FILE FRFULL
  75 FILES SEARCHED...
         14   FILE GBFULL
  84 FILES SEARCHED...
         89   FILE PATDPAFULL
       2151   FILE PCTFULL
  87 FILES SEARCHED...

  34 FILES HAVE ONE OR MORE ANSWERS,   92 FILES SEARCHED IN STNINDEX

L2    QUE ((ADONAL/BI OR AGRYPNAL/BI OR AMYLOFENE/BI OR BARBENYL/BI OR BARBIPHEN
          YL/BI OR BARBIPIL/BI OR BARBITA/BI OR BARBIVIS/BI OR BLU-PHEN/BI OR CR
          ATECIL/BI OR DORMIRAL/BI OR DOSCALUN/BI OR DUNERYL/BI OR ESKABARB/BI O
          R ETILFEN/BI OR EUNERYL/BI OR "FENEMAL RECIP"/BI OR FENEMAL/BI OR GARD
          ENAL/BI OR GARDEPANYL/BI OR HYSTEPS/BI OR LEPINAL/BI OR LEPINALETTEN/B
          I OR LIQUITAL/BI OR LIXOPHEN/BI OR LUBERGAL/BI OR LUMINAL/BI OR NEUROB
          ARB/BI OR NOPTIL/BI OR "NSC 128143"/BI OR "NSC 9848"/BI OR NUNOL/BI OR
```

```
          PHENAEMAL/BI OR PHENEMAL/BI OR PHENOBAR/BI OR PHENOBARBITAL/BI OR PHE
         NOBARBITONE/BI OR "PHENOBARBITURIC ACID"/BI OR PHENOLURIC/BI OR PHENON
         YL/BI OR "PHENYLETHYLBARBITURIC ACID"/BI OR PHENYLETHYLMALONYLUREA/BI
         OR PHENYRAL/BI OR PHOB/BI OR SEDONAL/BI OR SEDOPHEN/BI OR SEVENAL/BI O
         R SOLFOTON/BI OR SOMONAL/BI OR "STENTAL EXTENTABS"/BI OR TALPHENO/BI O
         R TEOLAXIN/BI OR TRIPHENATOL/BI OR VERSOMNAL/BI OR 11097-06-6/BI OR 46
         755-67-3/BI OR "5-ETHYL-5-PHENYLBARBITURIC ACID"/BI OR "5-PHENYL-5-ETH
         YLBARBITURIC ACID"/BI OR 50-06-6/BI)) AND PARKINSON?

=> file biosis embase medline uspatfull pctfull
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               4.88      12.52

FILE 'BIOSIS' ENTERED AT 12:49:03 ON 10 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:49:03 ON 10 AUG 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:49:03 ON 10 AUG 2006

FILE 'USPATFULL' ENTERED AT 12:49:03 ON 10 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 12:49:03 ON 10 AUG 2006
COPYRIGHT (C) 2006 Univentio

=> s (E1-E59)
L3      179514 ((ADONAL/BI OR AGRYPNAL/BI OR AMYLOFENE/BI OR BARBENYL/BI OR
               BARBIPHENYL/BI OR BARBIPIL/BI OR BARBITA/BI OR BARBIVIS/BI OR
               BLU-PHEN/BI OR CRATECIL/BI OR DORMIRAL/BI OR DOSCALUN/BI OR DUNER
               YL/BI OR ESKABARB/BI OR ETILFEN/BI OR EUNERYL/BI OR "FENEMAL
               RECIP"/BI OR FENEMAL/BI OR GARDENAL/BI OR GARDEPANYL/BI OR HYSTEP
               S/BI OR LEPINAL/BI OR LEPINALETTEN/BI OR LIQUITAL/BI OR LIXOPHEN/
               BI OR LUBERGAL/BI OR LUMINAL/BI OR NEUROBARB/BI OR NOPTIL/BI OR
               "NSC 128143"/BI OR "NSC 9848"/BI OR NUNOL/BI OR PHENAEMAL/BI OR
               PHENEMAL/BI OR PHENOBAR/BI OR PHENOBARBITAL/BI OR PHENOBARBITONE/
               BI OR "PHENOBARBITURIC ACID"/BI OR PHENOLURIC/BI OR PHENONYL/BI
               OR "PHENYLETHYLBARBITURIC ACID"/BI OR PHENYLETHYLMALONYLUREA/BI
               OR PHENYRAL/BI OR PHOB/BI OR SEDONAL/BI OR SEDOPHEN/BI OR SEVENAL
               /BI OR SOLFOTON/BI OR SOMONAL/BI OR "STENTAL EXTENTABS"/BI OR
               TALPHENO/BI OR TEOLAXIN/BI OR TRIPHENATOL/BI OR VERSOMNAL/BI OR
               11097-06-6/BI OR 46755-67-3/BI OR "5-ETHYL-5-PHENYLBARBITURIC
               ACID"/BI OR "5-PHENYL-5-ETHYLBARBITU

=> s l3 and parkinson?
L4        4507 L3 AND PARKINSON?

=> d l4 and tremor
'AND' IS NOT A VALID FORMAT
'TREMOR' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files.  Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ti

L4   ANSWER 1 OF 4507  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on
     STN
TI   An unusual way to get severe parkinsonism.


=> s l4 and  tremor
L5         755 L4 AND TREMOR
```

```
=> s l5 not py>2002
L6          284 L5 NOT PY>2002

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7           282 DUP REM L6 (2 DUPLICATES REMOVED)

=> d l7 1-20 ti

L7   ANSWER 1 OF 282  USPATFULL on STN
TI     B7-like polynucleotides, polypeptides, and antibodies

L7   ANSWER 2 OF 282  USPATFULL on STN
TI     Serine protease polynucleotides, polypeptides, and antibodies

L7   ANSWER 3 OF 282  USPATFULL on STN
TI     TGF-alpha polypeptides, functional fragments and methods of use therefor

L7   ANSWER 4 OF 282  USPATFULL on STN
TI     Human polynucleotides, polypeptides, and antibodies

L7   ANSWER 5 OF 282  USPATFULL on STN
TI     ADAM polynucleotides, polypeptides, and antibodies

L7   ANSWER 6 OF 282  USPATFULL on STN
TI     ADAM polynucleotides, polypeptides, and antibodies

L7   ANSWER 7 OF 282  USPATFULL on STN
TI     Protein tyrosine kinase receptor polynucleotides, polypeptides, and
       antibodies

L7   ANSWER 8 OF 282  USPATFULL on STN
TI     Nucleic acids, proteins, and antibodies

L7   ANSWER 9 OF 282  USPATFULL on STN
TI     Differential neurostimulation therapy driven by physiological context

L7   ANSWER 10 OF 282  USPATFULL on STN
TI     TGF-alpha polypeptides, functional fragments and methods of use therefor

L7   ANSWER 11 OF 282  USPATFULL on STN
TI     Nucleic acids, proteins, and antibodies

L7   ANSWER 12 OF 282  USPATFULL on STN
TI     Steroid hormone receptor polynucleotides, polypeptides, and antibodies

L7   ANSWER 13 OF 282  USPATFULL on STN
TI     Brain-associated inhibitor of tissue-type plasminogen activator

L7   ANSWER 14 OF 282  USPATFULL on STN
TI     Nucleic acids, proteins, and antibodies

L7   ANSWER 15 OF 282  USPATFULL on STN
TI     TM4SF receptor polynucleotides, polypeptides, and antibodies

L7   ANSWER 16 OF 282  USPATFULL on STN
TI     Immune system-related polynucleotides, polypeptides, and antibodies

L7   ANSWER 17 OF 282  USPATFULL on STN
TI     Nucleic acids, proteins, and antibodies

L7   ANSWER 18 OF 282  USPATFULL on STN
TI     Nucleic acids, proteins, and antibodies
```

```
L7   ANSWER 19 OF 282  USPATFULL on STN
TI     Serine/threonine phosphatase polynucleotides, polypeptides, and
       antibodies

L7   ANSWER 20 OF 282  USPATFULL on STN
TI     Calcium channel polynucleotides, polypeptides, and antibodies


=> file biosis embase medline
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       7.14      19.66

FILE 'BIOSIS' ENTERED AT 12:51:31 ON 10 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:51:31 ON 10 AUG 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:51:31 ON 10 AUG 2006

=> s (E1-E59)
L8       154244 ((ADONAL/BI OR AGRYPNAL/BI OR AMYLOFENE/BI OR BARBENYL/BI OR
                 BARBIPHENYL/BI OR BARBIPIL/BI OR BARBITA/BI OR BARBIVIS/BI OR
                BLU-PHEN/BI OR CRATECIL/BI OR DORMIRAL/BI OR DOSCALUN/BI OR DUNER
                YL/BI OR ESKABARB/BI OR ETILFEN/BI OR EUNERYL/BI OR "FENEMAL
                RECIP"/BI OR FENEMAL/BI OR GARDENAL/BI OR GARDEPANYL/BI OR HYSTEP
                S/BI OR LEPINAL/BI OR LEPINALETTEN/BI OR LIQUITAL/BI OR LIXOPHEN/
                BI OR LUBERGAL/BI OR LUMINAL/BI OR NEUROBARB/BI OR NOPTIL/BI OR
                "NSC 128143"/BI OR "NSC 9848"/BI OR NUNOL/BI OR PHENAEMAL/BI OR
                PHENEMAL/BI OR PHENOBAR/BI OR PHENOBARBITAL/BI OR PHENOBARBITONE/
                BI OR "PHENOBARBITURIC ACID"/BI OR PHENOLURIC/BI OR PHENONYL/BI
                OR "PHENYLETHYLBARBITURIC ACID"/BI OR PHENYLETHYLMALONYLUREA/BI
                OR PHENYRAL/BI OR PHOB/BI OR SEDONAL/BI OR SEDOPHEN/BI OR SEVENAL
                /BI OR SOLFOTON/BI OR SOMONAL/BI OR "STENTAL EXTENTABS"/BI OR
                TALPHENO/BI OR TEOLAXIN/BI OR TRIPHENATOL/BI OR VERSOMNAL/BI OR
                11097-06-6/BI OR 46755-67-3/BI OR "5-ETHYL-5-PHENYLBARBITURIC
                ACID"/BI OR "5-PHENYL-5-ETHYLBARBITU

=> s l8 and dystonia
L9          157 L8 AND DYSTONIA

=> s l9 not py>2002
L10         113 L9 NOT PY>2002

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11          99 DUP REM L10 (14 DUPLICATES REMOVED)

=> s l11 nad (treatment or treating)
MISSING OPERATOR L11 NAD
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l11 and (treatment or treating)
L12          38 L11 AND (TREATMENT OR TREATING)

=> d l12 -138 ti

L12  ANSWER 1 OF 38  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on STN
TI   TorsinA in PC12 cells: Primary ER localization and response to oxidative
     stress.

L12  ANSWER 2 OF 38  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on STN
TI   Paradoxical aggravation of paroxysmal dystonia during chronic
```

treatment with phenobarbital in a genetic rodent model.

L12 ANSWER 3 OF 38 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Alterations in pharmacological sensitivity of GABAergic but not dopaminergic and glutamatergic systems during ontogenesis in dystonic mutant hamsters.

L12 ANSWER 4 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Psychiatric comorbidity in patients with developmental disorders and epilepsy: A practical approach to its diagnosis and treatment.

L12 ANSWER 5 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [Psychopharmacotherapy in elderly].
PSIHOFARMAKOTERAPIJA U STARIJOJ ZIVOTNOJ DOBI.

L12 ANSWER 6 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis.

L12 ANSWER 7 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Treatment of psychosis, aggression, and irritability in patients with epilepsy.

L12 ANSWER 8 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Essential tremor.

L12 ANSWER 9 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Rationalization of an antiepileptic drug formulation.

L12 ANSWER 10 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Selective decrease in central nervous system serotonin turnover in children with dopa-nonresponsive dystonia.

L12 ANSWER 11 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: Impaired glucose transport into brain - A review.

L12 ANSWER 12 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Infantile-onset paroxysmal dystonia: A diagnostic dilemma.

L12 ANSWER 13 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Effectiveness of lamotrigine in children with paroxysmal kinesigenic choreoathetosis.

L12 ANSWER 14 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Adverse response to methylphenidate in combination with valproic acid.

L12 ANSWER 15 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders.

L12 ANSWER 16 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Pharmacologic treatment of tremor.

L12 ANSWER 17 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Developmental pharmacology: Past, present and future.

L12 ANSWER 18 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Oral pharmacotherapy for the movement disorders of cerebral palsy.

L12 ANSWER 19 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI New antidepressant drugs and the treatment of depression in the medically ill patient.

L12 ANSWER 20 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Medical treatment of dystonias.

L12 ANSWER 21 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Primary dystonias. Current therapeutic recommendations.

L12 ANSWER 22 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Seizures and dystonia in an adolescent with a toxic ingestion.

L12 ANSWER 23 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [Nimodipine in drug-resistant childhood epilepsy: A double-blind, placebo-controlled trial].
IMPIEGO DELLA NIMODIPINA NELL'EPILESSIA FARMACORESISTENTE: STUDIO IN DOPPIO CIECO, PLACEBO-CONTROLLATO.

L12 ANSWER 24 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Tiapride as treatment for certain patients with idiopathic torsion dystonia.

L12 ANSWER 25 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Abnormal paroxysomal movements during sleep: Hypnogenic paroxysmal dystonia or focal epilepsy?.

L12 ANSWER 26 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Treatment of hyperkinetic movement disorders.

L12 ANSWER 27 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Pimozide treatment of tic and Tourette disorders.

L12 ANSWER 28 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Neuroleptic-associated tardive syndromes.

L12 ANSWER 29 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Adverse neuropsychiatric effect of anticonvulsant drugs.

L12 ANSWER 30 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats.

L12 ANSWER 31 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Meige's syndrome: Clinical, pharmacological and radiological observations.

L12 ANSWER 32 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Dystonia associated with carbamazepine administration: Experience in brain-damaged children.

L12 ANSWER 33 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Parenteral treatment of acute psychotic patients with agitation: A review.

L12 ANSWER 34 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Clonazepam ('Rivotril' Roche): an independent report.

L12 ANSWER 35 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Iatrogenic extrapyramidal disorders.

L12 ANSWER 36 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

L12 ANSWER 37 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Treatment of acute psychotic patients with loxapine parenterally.

L12 ANSWER 38 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI On the relation of dystonic movements to serum thyroxine levels.

=> d l12 16 20 21 26 28 32 ti abs bib

L12 ANSWER 16 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Pharmacologic treatment of tremor.
AB Tremor is a common neurologic symptom that can also be incapacitating to the patient, so effective therapy is needed. The causes of tremor are heterogeneous. Essential tremor (ET) and the tremor associated with Parkinson's disease (PD) are the most common encountered in clinical practice. β-Adrenergic blockers and primidone remain the mainstay of treatment for ET, whereas carbidopa/levodopa and anticholinergics are most beneficial in PD. However, the efficacy of various other medications has been studied in ET and PD, and also in patients with tremor resulting from other conditions, with varying results.
AN 1998383980 EMBASE
TI Pharmacologic treatment of tremor.
AU Wasielewski P.G.; Burns J.M.; Koller W.C.
CS Dr. P.G. Wasielewski, Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7314, United States
SO Movement Disorders, (1998) Vol. 13, No. SUPPL. 3, pp. 90-100. .
Refs: 152
ISSN: 0885-3185 CODEN: MOVDEA
CY United States
DT Journal; Conference Article
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
038 Adverse Reactions Titles

050 Epilepsy
LA English
SL English
ED Entered STN: 3 Dec 1998
Last Updated on STN: 3 Dec 1998

L12 ANSWER 20 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Medical treatment of dystonias.
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
AN 95266769 EMBASE
DN 1995266769
TI Medical treatment of dystonias.
AU Yamamura Y.; Kamei E.
CS Institute of Health Sciences, Hiroshima Univ. School of Medicine, Higashi senda 1-1-89,Naka-ku, Hiroshima 730, Japan
SO Japanese Journal of Neuropsychopharmacology, (1995) Vol. 17, No. 8, pp. 537-544. .
ISSN: 0388-7588 CODEN: SSYAD7
CY Japan
DT Journal; Article
FS 008 Neurology and Neurosurgery
030 Pharmacology
037 Drug Literature Index
LA Japanese
ED Entered STN: 26 Sep 1995
Last Updated on STN: 26 Sep 1995

L12 ANSWER 21 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Primary dystonias. Current therapeutic recommendations.
AB Dystonia is a syndrome of sustained muscle contractions, frequently causing twisting and repetitive movements or abnormal postures. Primary and secondary dystonias are distinguishable and both can be classified by the extent of body involvement as generalised, focal, segmental, multifocal and hemidystonic. The treatment of primary dystonias involves the exclusion of secondary causes such as drug-induced (particularly common with dopamine blocking agents) and Wilson's disease. This should be followed by a trial of levodopa, especially in cases of onset in the first 3 decades of life. Symptomatic oral pharmacotherapy includes anticholinergic agents, baclofen, clonazepam and carbamazepine. The use of intrathecal baclofen infused by a surgically implanted pump has been advocated for intractable axial dystonia. Botulinum toxin A injections have become the treatment of choice of many focal dystonias (e.g. blepharospasm, cervical dystonia, jaw closure dystonia, hyperadduction laryngeal dystonia). Jaw opening dystonia, writer's cramp and more complex limb dystonias may also benefit from botulinum toxin A. Paroxysmal kinesigenic dystonias are responsive to phenytoin, carbamazepine, phenobarbital (phenobarbitone), primidone and diazepam. Paroxysmal nonkinesigenic dystonias do not respond as well to these agents and may warrant a trial of other agents such as acetazolamide, clonazepam, oxazepam, baclofen or anticholinergic agents. Surgical interventions include stereotactic thalamotony for severe generalised dystonia unresponsive to intensive pharmacological trials, and 'peripheral' surgeries designed to address specific types of focal dystonia that are unresponsive to botulinum toxin (e.g. orbital myectomy for blepharospasm and cervical ramisectomy for cervical dystonia). Orthotic devices for limb dystonia, and writing aid devices and other physical therapy measures can provide assistance in selected patients.
AN 95074458 EMBASE
DN 1995074458
TI Primary dystonias. Current therapeutic recommendations.

AU Singer C.; Weiner W.J.
CS Department of Neurology, University of Miami School Medicine, 1501 NW 9th Avenue,Miami, FL 33136, United States
SO CNS Drugs, (1995) Vol. 3, No. 3, pp. 186-193. .
ISSN: 1172-7047 CODEN: CNDREF
CY New Zealand
DT Journal; (Short Survey)
FS 008 Neurology and Neurosurgery
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 5 Apr 1995
Last Updated on STN: 5 Apr 1995

L12 ANSWER 26 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Treatment of hyperkinetic movement disorders.
AB Movement disorders are subdivided based on a variety of criteria. One useful and popular approach to movement disorders, based on clinical phenoimenology, categorizes these disorders into two groups, those displaying a pverty of movement (akinesia) and those displaying excessive movement (hyperkinesia). This article discusses diagnosis and treatment of the latter. By necessity, certain hyperkinesias such as hyperexplexia, akathisia, and restless leg syndrome are omitted or only briefly discussed. The major hyperkinesias, dystonia, tremor, tics, chorea (including tardive dyskinesia and ballism), and myoclonus are reviewed and a guide to practical management emphasizing symptomatic treatment if presented.
AN 90124788 EMBASE
DN 1990124788
TI Treatment of hyperkinetic movement disorders.
AU Bressman S.B.; Greene P.E.
CS Department of Neurology, Neurological Institute, Columbia Presbyterian Medical Center, New York, NY 10032, United States
SO Neurologic Clinics, (1990) Vol. 8, No. 1, pp. 51-75+x. .
ISSN: 0733-8619 CODEN: NECLEG
CY United States
DT Journal; General Review
FS 008 Neurology and Neurosurgery
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 13 Dec 1991
Last Updated on STN: 13 Dec 1991

L12 ANSWER 28 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Neuroleptic-associated tardive syndromes.
AB We have briefly reviewed the literature on late-onset akathisia, dystonia, and Tourette-like syndrome in patients on long-term neuroleptic treatment. To date, there is no satisfactory epidemiology or other evidence directly implicating neuroleptics in the etiology of these so-called tardive syndromes. Similarities between these disorders and tardive dyskinesia, however, make them worthy of some consideration.
AN 86112411 EMBASE
DN 1986112411
TI Neuroleptic-associated tardive syndromes.
AU Jeste D.V.; Wisniewski A.A.; Wyatt R.J.
CS Neuropsychiatry Branch, St. Elizabeths Hospital, NIMH Intramural Program, Washington, DC 20032, United States

SO Psychiatric Clinics of North America, (1986) Vol. 9, No. 1, pp. 183-192. .
CODEN: PCAMDG
CY United States
DT Journal
FS 038 Adverse Reactions Titles
032 Psychiatry
008 Neurology and Neurosurgery
037 Drug Literature Index
030 Pharmacology
LA English
ED Entered STN: 10 Dec 1991
Last Updated on STN: 10 Dec 1991

L12 ANSWER 32 OF 38 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Dystonia associated with carbamazepine administration: Experience in brain-damaged children.
AB Carbamazepine is an anticonvulsant most effective in treating complex partial and generalized tonic-clonic seizures. We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use. The patients, a 4-yr-old with microcephaly and severe retardation, a 1-yr-old with cerebral dysgenesis, and a 5-yr-old with spastic quadriplegia and mild retardation, all had seizures unresponsive to multiple anticonvulsant combinations.In all three patients, carbamazepine was introduced and gradually increased to a maximum dosage of 25 mg/kg of body weight per day. Dystonic symptoms began two to three weeks after introduction of therapy and subsided within three weeks after discontinuation. In one child, a second course of carbamazepine resulted in a return of the dystonia. The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.
AN 79125772 EMBASE
DN 1979125772
TI Dystonia associated with carbamazepine administration: Experience in brain-damaged children.
AU Crosley C.J.; Swender P.T.
CS Dept. Neurol., Upstate Med. Cent., SUNY, Syracuse, N.Y., United States
SO Pediatrics, (1979) Vol. 63, No. 4, pp. 612-615. .
CODEN: PEDIAU
CY United States
DT Journal
FS 007 Pediatrics and Pediatric Surgery
008 Neurology and Neurosurgery
037 Drug Literature Index
038 Adverse Reactions Titles
050 Epilepsy
LA English

=> s l8 and parkinson?
L13 240 L8 AND PARKINSON?

=> s l13 not py>2002
L14 170 L13 NOT PY>2002

=> dup rem l14
PROCESSING COMPLETED FOR L14
L15 141 DUP REM L14 (29 DUPLICATES REMOVED)

=> s l15 and tremor
L16 41 L15 AND TREMOR

=> d l16 1-41 ti

L16 ANSWER 1 OF 41 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI PHARMACOLOGICAL AND BIOCHEMICAL CHARACTERIZATION OF ANTI PARKINSON DRUGS IN RESERPINIZED MICE.

L16 ANSWER 2 OF 41 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI ANTI CONVULSANT EFFECT OF PHTHALAZINO-2 3-B-PHTHALAZINE-5 14H 12 7H-DIONE L-5418 PART 1 BEHAVIORAL EFFECT.

L16 ANSWER 3 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI The management of tremor.

L16 ANSWER 4 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Essential tremor.

L16 ANSWER 5 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Hot flashes: The old and the new, what is really true?.

L16 ANSWER 6 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [Disorders of the motor system induced by anticonvulsants]. ANTIEPILEPTIKAINDUZIERTE STORUNGEN DES MOTORISCHEN SYSTEMS.

L16 ANSWER 7 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI The management of tremor.

L16 ANSWER 8 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [New aspects on therapy in tremor disorders]. NEUES ZUR TREMOR-THERAPIE.

L16 ANSWER 9 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Nonparkinsonian tremors.

L16 ANSWER 10 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [Tremor - New treatment options]. TREMOR - NEUE THERAPIEOPTIONEN.

L16 ANSWER 11 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Pharmacologic treatment of tremor.

L16 ANSWER 12 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Acute hyponatremia and neuroleptic malignant syndrome in Parkinson 's disease.

L16 ANSWER 13 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Dronabinol in tremor.

L16 ANSWER 14 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [Tremor]. LES TREMBLEMENTS.

L16 ANSWER 15 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI A combined clinical and neurophysiological approach to the study of patients with tremor.

L16 ANSWER 16 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [Tremor].
TREMBLEMENT. ORIENTATION DIAGNOSTIQUE.

L16 ANSWER 17 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Non-parkinsonian tremor.

L16 ANSWER 18 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Essential tremor.

L16 ANSWER 19 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Tremors.

L16 ANSWER 20 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Tremors.

L16 ANSWER 21 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Essential tremor in Nigerians: A prospective study of 35 cases.

L16 ANSWER 22 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Drugs and tremor.

L16 ANSWER 23 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Movement disorders in the elderly.

L16 ANSWER 24 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [Tremors in old people].
LES TREMBLEMENTS DU SUJET AGE.

L16 ANSWER 25 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Essential tremor.

L16 ANSWER 26 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Phenobarbital and propranolol in essential tremor: A double-blind controlled clinical trial.

L16 ANSWER 27 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Essential tremor and buccolinguofacial dyskinesias.

L16 ANSWER 28 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Double-blind controlled study of primidone in essential tremor: Preliminary results.

L16 ANSWER 29 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Essential tremor: Response to primidone.

L16 ANSWER 30 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [When should one think drugs?].
QUAND FAUT-IL PENSER MEDICAMENTS?.

L16 ANSWER 31 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Essential tremor.

L16 ANSWER 32 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Methanol poisoning: A clinical and pathological study.

L16 ANSWER 33 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI A therapeutic approach and objective test in the treatment of tremor.

L16 ANSWER 34 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [Conservative therapeutic approach to tremor and attempt at objectification].
APPROCHE THERAPEUTIQUE CONSERVATRICE DU TREMBLEMENT ET ESSAI D'OBJECTIVATION.

L16 ANSWER 35 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Involuntary movements not due to Parkinsonism.

L16 ANSWER 36 OF 41 MEDLINE on STN
TI [Treatment of essential tremor].
Le traitement du tremblement essentiel.

L16 ANSWER 37 OF 41 MEDLINE on STN
TI Essential tremor: an overview.

L16 ANSWER 38 OF 41 MEDLINE on STN
TI Essential tremor.

L16 ANSWER 39 OF 41 MEDLINE on STN
TI [Idiopathic rest, attitude and action tremor. Anatomo-clinical stude of 1 case].
Tremblemetn idiopathique de repos, d'attitude et d'action. Etude anatomo-clinique d'une observation.

L16 ANSWER 40 OF 41 MEDLINE on STN
TI [Clinical tests of C.E. 10010 in tremor and abnormal movements].
Essais cliniques du 10010 C.E. dans les tremblements et les mouvements anormaux.

L16 ANSWER 41 OF 41 MEDLINE on STN
TI A CONTROLLED CLINICAL TRIAL OF ALPHA METHYL DOPA IN PARKINSONIAN TREMOR.

=> d l16 1 3 4 7 8 10 11 16 20 41 ti abs bib

L16 ANSWER 1 OF 41 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI PHARMACOLOGICAL AND BIOCHEMICAL CHARACTERIZATION OF ANTI PARKINSON DRUGS IN RESERPINIZED MICE.
AB The effect of various clinically useful anti-parkinson drugs was examined on reserpine-induced catatonia and oxotremorine-induced tremors in mice. Amantadine, apomorphine, atropine, clonidine and L-dopa significantly reversed reserpine-induced catatonia, but no highly significant changes in brain dopamine and noradrenaline (norepinephrine) levels were seen with the 1st 4 drugs, at the time of peak pharmacological antagonism. Chlorpromazine, imipramine, nitroxazepine, morphine and sodium phenobarbital were ineffective in reversing reserpine-induced extrapyramidal symptoms. The anticholinergic agent

atropine and chlorpromazine were the most potent in inhibiting oxotremorine-induced tremors.
AN 1980:219282 BIOSIS
DN PREV198070011778; BA70:11778
TI PHARMACOLOGICAL AND BIOCHEMICAL CHARACTERIZATION OF ANTI PARKINSON DRUGS IN RESERPINIZED MICE.
AU DAVID J [Reprint author]; KAUL C L; GREWAL R S
CS CIBA-GEIGY RES CENT, GOREGAON, BOMBAY 400063, MAHARASHTRA, INDIA
SO Indian Journal of Experimental Biology, (1979) Vol. 17, No. 8, pp. 760-764.
CODEN: IJEBA6. ISSN: 0019-5189.
DT Article
FS BA
LA ENGLISH

L16 ANSWER 3 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI The management of tremor.
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
AN 2005524535 EMBASE
TI The management of tremor.
AU Bain P.G.
CS Dr. P.G. Bain, Department of Neurosciences, Imperial College, Charing Cross Hospital Campus, Fulham Palace Road, London W6 8RF, United Kingdom. p.bain@ic.ac.uk
SO Neurology in Practice, (2002) Vol. 72, No. 1, pp. i3-i9. .
Refs: 33
ISSN: 1473-7086 CODEN: NPERAF
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
LA English
ED Entered STN: 29 Dec 2005
Last Updated on STN: 29 Dec 2005

L16 ANSWER 4 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Essential tremor.
AB Essential tremor (ET), also known as benign essential tremor, is probably the most common movement disorder, with a prevalence of approximately 1% in the population. ET frequently presents with postural and/or action tremor which most commonly affects the upper limbs. Moderate and severe ET often lead to significant physical and emotional disability resulting in reduced quality of life. The exact pathophysiology of ET is not understood but approximately half the patients have a clear autosoma dominant mode of inheritance. Pharmacological treatment, usually in the form of propranolol or primidone, is usually necessary in moderate or severe ET but the response is frequently modest. Stereotactic surgery can be very effective in patients with severe disease that is unresponsive to pharmacological treatment.
AN 2002447042 EMBASE
TI Essential tremor.
AU Malik N.; Amar K.
CS Dr. K. Amar, Dept. of Gen. and Geriatric Medicine, Royal Bournemouth Hospital, Castle Lane East, Bournemouth BH7 7DW, United Kingdom
SO CME Journal Geriatric Medicine, (2002) Vol. 4, No. 3, pp. 117-121. .
Refs: 26
ISSN: 1367-8914 CODEN: CJGMAH
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
005 General Pathology and Pathological Anatomy
017 Public Health, Social Medicine and Epidemiology

037 Drug Literature Index
030 Pharmacology
022 Human Genetics
020 Gerontology and Geriatrics
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 27 Dec 2002
Last Updated on STN: 27 Dec 2002

L16 ANSWER 7 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI The management of tremor.
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
AN 2002085547 EMBASE
TI The management of tremor.
AU Bain P.G.
CS Dr. P.G. Bain, Department of Neurosciences, Imperial College, Charing Cross Hospital Campus, Fulham Palace Road, London W6 8RF, United Kingdom. p.bain@ic.ac.uk
SO Neurology in Practice, (2002) Vol. 72, No. 5 SUPPL. 1, pp. i3-i9. .
Refs: 33
ISSN: 1473-7086 CODEN: NPERAF
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
ED Entered STN: 21 Mar 2002
Last Updated on STN: 21 Mar 2002

L16 ANSWER 8 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [New aspects on therapy in tremor disorders].
NEUES ZUR TREMOR-THERAPIE.
AB Betablockers like propranolol and the anticonvulsant primidone still represent the mainstay of pharmacotherapy in the most common tremor disorder, i.e. essential tremor. Trials of local injections of botulinum toxin are indicated in head and voice tremor, especially if it is a dystonic tremor. Deep brain stimulation which allows non-destructive functional stereotactical surgery is an option for otherwise refractory tremor syndromes, which can have a profound impact on quality of life. The stereotactical target for tremor in Parkinson's disease has changed. Nowadays, VIM thalamus is approached for non-Parkinsonian-tremor and subthalamic nucleus is presently the favoured target for Parkinson's disease.
AN 2002010922 EMBASE
TI [New aspects on therapy in tremor disorders].
NEUES ZUR TREMOR-THERAPIE.
AU Ceballos-Baumann A.O.; Conrad B.
CS Dr. A.O. Ceballos-Baumann, Neurologische Klinik der TU Munchen, Klinikum Rechts der Isor, Mohlstrosse 28, D-81675 Munchen, Germany. a.ceballos@lrz.lum.de
SO Nervenheilkunde, (2001) Vol. 20, No. 10, pp. 537-544. .
Refs: 49
ISSN: 0722-1541 CODEN: NERVDI
CY Germany
DT Journal; General Review
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
038 Adverse Reactions Titles
LA German

SL English; German
ED Entered STN: 17 Jan 2002
Last Updated on STN: 17 Jan 2002

L16 ANSWER 10 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [Tremor - New treatment options].
TREMOR - NEUE THERAPIEOPTIONEN.
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
AN 2000439082 EMBASE
TI [Tremor - New treatment options].
TREMOR - NEUE THERAPIEOPTIONEN.
AU Ceballos-Baumann A.O.; Boecker H.
CS Dr. A.O. Ceballos-Baumann, Neurologische Klinik der TU Munchen, Klinikum rechts der Isar, Mohlstrasse 28, 81675 Munchen, Germany.
a.ceballos@lrz.tu-muenchen.de
SO Internist, (2000) Vol. 41, No. 12, pp. 1353-1362. .
Refs: 47
ISSN: 0020-9554 CODEN: INTEAG
CY Germany
DT Journal; General Review
FS 006 Internal Medicine
008 Neurology and Neurosurgery
037 Drug Literature Index
LA German
ED Entered STN: 11 Jan 2001
Last Updated on STN: 11 Jan 2001

L16 ANSWER 11 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Pharmacologic treatment of tremor.
AB Tremor is a common neurologic symptom that can also be incapacitating to the patient, so effective therapy is needed. The causes of tremor are heterogeneous. Essential tremor (ET) and the tremor associated with Parkinson's disease (PD) are the most common encountered in clinical practice. β-Adrenergic blockers and primidone remain the mainstay of treatment for ET, whereas carbidopa/levodopa and anticholinergics are most beneficial in PD. However, the efficacy of various other medications has been studied in ET and PD, and also in patients with tremor resulting from other conditions, with varying results.
AN 1998383980 EMBASE
TI Pharmacologic treatment of tremor.
AU Wasielewski P.G.; Burns J.M.; Koller W.C.
CS Dr. P.G. Wasielewski, Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7314, United States
SO Movement Disorders, (1998) Vol. 13, No. SUPPL. 3, pp. 90-100. .
Refs: 152
ISSN: 0885-3185 CODEN: MOVDEA
CY United States
DT Journal; Conference Article
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
038 Adverse Reactions Titles
050 Epilepsy
LA English
SL English
ED Entered STN: 3 Dec 1998
Last Updated on STN: 3 Dec 1998

L16 ANSWER 16 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI [Tremor].
TREMBLEMENT. ORIENTATION DIAGNOSTIQUE.

DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
AN 93022294 EMBASE
DN 1993022294
TI [Tremor].
TREMBLEMENT. ORIENTATION DIAGNOSTIQUE.
AU Zuber M.
CS Service de Neurologie, Hopital Sainte-Anne, Centre Raymond Garcia, 1, Rue Cabanis,75674 Paris Cedex, France
SO Revue du Praticien, (1992) Vol. 42, No. 20, pp. 2639-2641. .
ISSN: 0035-2640 CODEN: REPRA3
CY France
DT Journal; (Short Survey)
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
LA French
ED Entered STN: 21 Feb 1993
Last Updated on STN: 21 Feb 1993

L16 ANSWER 20 OF 41 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Tremors.
AB In this article, normal tremor and common types of pathologic tremors seen in the elderly are defined and described along with a review of current treatments. Problems of differential diagnosis are emphasized.
AN 89285183 EMBASE
DN 1989285183
TI Tremors.
AU Cleeves L.; Findley L.J.
CS MRC Neuro-Otology Unit, Institute of Neurology, National Hospital, London WC1N, United Kingdom
SO Medical Clinics of North America, (1989) Vol. 73, No. 6, pp. 1307-1319. .
ISSN: 0025-7125 CODEN: MCNAA
CY United States
DT Journal
FS 008 Neurology and Neurosurgery
020 Gerontology and Geriatrics
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 12 Dec 1991
Last Updated on STN: 12 Dec 1991

L16 ANSWER 41 OF 41 MEDLINE on STN
TI A CONTROLLED CLINICAL TRIAL OF ALPHA METHYL DOPA IN PARKINSONIAN TREMOR.
AN 64040864 MEDLINE
DN PubMed ID: 14083221
TI A CONTROLLED CLINICAL TRIAL OF ALPHA METHYL DOPA IN PARKINSONIAN TREMOR.
AU MARSH D O; SCHNIEDEN H; MARSHALL J
SO Journal of neurology, neurosurgery, and psychiatry, (1963 Dec) Vol. 26, pp. 505-10.
Journal code: 2985191R. ISSN: 0022-3050.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
EM 199612
ED Entered STN: 16 Jul 1999
Last Updated on STN: 16 Jul 1999
Entered Medline: 1 Dec 1996

=> d his

```
      (FILE 'HOME' ENTERED AT 12:43:15 ON 10 AUG 2006)

      FILE 'REGISTRY' ENTERED AT 12:43:25 ON 10 AUG 2006
L1             1 S PHENOBARBITAL/CN
                 SEL L1

      INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
      AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
      CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
      DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:44:01 ON 10 AUG 2006
                 SEA (E1-E59) AND PARKINSON?
                 ---------
               11   FILE ADISCTI
                5   FILE ADISINSIGHT
               10   FILE ADISNEWS
               31   FILE BIOSIS
                3   FILE BIOTECHABS
                3   FILE BIOTECHDS
                6   FILE BIOTECHNO
               48   FILE CAPLUS
               55   FILE DDFB
               46   FILE DDFU
                4   FILE DGENE
               55   FILE DRUGB
               78   FILE DRUGU
              177   FILE EMBASE
                6   FILE ESBIOBASE
               33   FILE IFIPAT
                3   FILE IMSRESEARCH
                1   FILE JICST-EPLUS
                4   FILE LIFESCI
               32   FILE MEDLINE
                6   FILE PASCAL
                2   FILE PHIN
                8   FILE PROMT
               27   FILE SCISEARCH
               37   FILE TOXCENTER
             2116   FILE USPATFULL
              266   FILE USPAT2
               56   FILE WPIDS
               56   FILE WPINDEX
              207   FILE EPFULL
               15   FILE FRFULL
               14   FILE GBFULL
               89   FILE PATDPAFULL
             2151   FILE PCTFULL
L2               QUE ((ADONAL/BI OR AGRYPNAL/BI OR AMYLOFENE/BI OR BARBENYL/BI O
                 ---------

      FILE 'BIOSIS, EMBASE, MEDLINE, USPATFULL, PCTFULL' ENTERED AT 12:49:03 ON
      10 AUG 2006
L3         179514 S (E1-E59)
L4           4507 S L3 AND PARKINSON?
L5            755 S L4 AND  TREMOR
L6            284 S L5 NOT PY>2002
L7            282 DUP REM L6 (2 DUPLICATES REMOVED)

      FILE 'BIOSIS, EMBASE, MEDLINE' ENTERED AT 12:51:31 ON 10 AUG 2006
L8         154244 S (E1-E59)
L9            157 S L8 AND DYSTONIA
L10           113 S L9 NOT PY>2002
L11            99 DUP REM L10 (14 DUPLICATES REMOVED)
L12            38 S L11 AND (TREATMENT OR TREATING)
L13           240 S L8 AND PARKINSON?
```

```
L14          170 S L13 NOT PY>2002
L15          141 DUP REM L14 (29 DUPLICATES REMOVED)
L16           41 S L15 AND TREMOR

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                     55.66      75.32

STN INTERNATIONAL LOGOFF AT 12:58:07 ON 10 AUG 2006
```